[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1416
1. Medina EA, Arias VL: [Middle ear adenoma]. Biomedica; 2009 Sep;29(3):348-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herein, a middle ear neoplasm is described that became apparent because of its appearance in the external ear duct as it protruded from the middle ear through the eardrum.
  • Following resection, the specimen was determined to be a benign epithelial tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20436986.001).
  • [ISSN] 0120-4157
  • [Journal-full-title] Biomédica : revista del Instituto Nacional de Salud
  • [ISO-abbreviation] Biomedica
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Colombia
  •  go-up   go-down


2. Miot HA, Miot LD, da Costa AL, Matsuo CY, Stolf HO, Marques ME: Association between solitary keratoacanthoma and cigarette smoking: a case-control study. Dermatol Online J; 2006;12(2):2
MedlinePlus Health Information. consumer health - Smoking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Solitary keratoacanthoma (KA) is a common benign epithelial tumor of the skin characterized by rapid growth and a tendency toward spontaneous regression.
  • The exact etiology and classification of KA are a matter of debate.

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638395.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Friedrich RE, Li L, Knop J, Giese M, Schmelzle R: Pleomorphic adenoma of the salivary glands: analysis of 94 patients. Anticancer Res; 2005 May-Jun;25(3A):1703-5
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic adenoma is a benign epithelial tumor of adenoid structure preferentially arising from the parotid gland.
  • It was shown that complete tumor excision is a curative measure and recurrence is likely in incompletely excised tumors.
  • The aim of this study was to analyse the outcome of patients with pleomorphic adenoma from salivary glands in order to evaluate the surgical strategy of a single institution.
  • The tumor occurred more often in females than in males (45:28, parotid).
  • CONCLUSION: Pleomorphic adenoma from salivary glands is a benign tumor.
  • However, in a noteworthy number of patients, inside the benign tumor a phenotype develops with distinct properties of malignancy.
  • Multinodular tumors are prone to recurrent disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033086.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


Advertisement
4. Torlakovic E, Lilleby W, Berner A, Torlakovic G, Chibbar R, Furre T, Fosså SD: Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma. Int J Cancer; 2005 Nov 10;117(3):381-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression, distribution and the role of steroid receptors in benign and malignant untreated prostate tissues is well recognized, however, the status of steroid receptors in prostate after radiotherapy (RT) for adenocarcinoma has not yet been studied fully.
  • Significantly higher level of ER-beta expression was found in post-radiation samples of prostate adenocarcinoma and benign epithelium.
  • Tumor AR expression did not change significantly.
  • High levels of pretreatment tumor ER-beta were associated with local recurrence after RT and decreased biochemical recurrence-free survival (p = 0.028).
  • Upregulation of all steroid receptors in the prostate stroma and upregulation of ER-beta in the tumor epithelium after RT, may represent a protective tissue response to radiation-induced tissue injury.
  • Although stromal AR was doubled after RT, the tumor and benign epithelium expression of AR seemed resistant to change by RT.
  • [MeSH-minor] Biopsy, Needle. Cell Line, Tumor. Epithelial Cells / pathology. Humans. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15900599.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Steroid
  •  go-up   go-down


5. Brancatelli G, Federle MP, Vullierme MP, Lagalla R, Midiri M, Vilgrain V: CT and MR imaging evaluation of hepatic adenoma. J Comput Assist Tomogr; 2006 Sep-Oct;30(5):745-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatic adenoma is a rare benign epithelial tumor that is usually encountered in young women who use oral contraceptives.
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Focal Nodular Hyperplasia / diagnosis. Humans. Liver / pathology. Liver / radiography. Middle Aged. Rare Diseases

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954922.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Halbritter SA, Altermatt HJ, Caversaccio M, Bornstein MM: Apocrine papillary cystadenoma of a minor salivary gland on the lower lip: case presentation. Quintessence Int; 2009 Feb;40(2):167-9
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine papillary cystadenoma of a minor salivary gland on the lower lip: case presentation.
  • Cystadenomas are a rare, painless, and slow-growing benign epithelial tumor of the salivary gland.
  • This article describes the case of a papillary cystadenoma in the lower lip of a 46-year-old man.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169449.001).
  • [ISSN] 1936-7163
  • [Journal-full-title] Quintessence international (Berlin, Germany : 1985)
  • [ISO-abbreviation] Quintessence Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


7. Bouraoui S, Khaddar KR, Ben Tekaya N, Kchir N, Mekni A, Ben Osman DA, Zitouna MM, Haouet S: [Warty dyskeratoma or "follicular dykeratoma": a clinicopathologic features of a new entity]. Tunis Med; 2005 Apr;83(4):227-9
MedlinePlus Health Information. consumer health - Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Warty dyskeratoma or "follicular dykeratoma": a clinicopathologic features of a new entity].
  • INTRODUCTION: Warty dyskeratoma is a rare, benign, epithelial tumor characterized by a variable clinicopathologic spectrum.
  • DISCUSSION: Warty dyskeratoma is an epithelial tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966669.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


8. Ekici AI, Ekici S, Gürel B, Altinok G, Erkan I, Güngen Y: Benign mixed epithelial and stromal tumor of the kidney. ScientificWorldJournal; 2006;6:615-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign mixed epithelial and stromal tumor of the kidney.
  • The renal mass was found to be a benign, biphasic tumor composed of an epithelial component, consisting of ducts of variable size scattered within a mesenchymal component, composed of spindle cells arranged in sheets and fascicles.
  • The diagnosis of benign mixed epithelial and stromal tumor of the kidney is rendered.
  • [MeSH-minor] Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Nephrectomy. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16752009.001).
  • [ISSN] 1537-744X
  • [Journal-full-title] TheScientificWorldJournal
  • [ISO-abbreviation] ScientificWorldJournal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Chiu NC, Wu HM, Chou YH, Li WY, Chiou YY, Guo WY, Chang CY: Basal cell adenoma versus pleomorphic adenoma of the parotid gland: CT findings. AJR Am J Roentgenol; 2007 Nov;189(5):W254-61
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Basal cell adenoma is a rare benign epithelial tumor of the salivary gland.
  • We also compare CT findings of basal cell adenoma with those of pleomorphic adenoma, the most common parotid tumor, to determine whether any features on CT can help differentiate these two entities.
  • They are generally round, well-circumscribed tumors that show heterogeneous enhancement on CT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954621.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Kusafuka K, Ueno T, Kurihara K, Murata T, Yurikusa T, Henmi H, Akane M, Ota Y, Kameya T: Cystadenoma of the palate: immunohistochemistry of mucins. Pathol Int; 2008 Aug;58(8):524-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystadenoma is a relatively rare benign epithelial tumor of the salivary glands, and described herein is an additional case.
  • Histologically, the tumor was composed of bilayered columnar epithelium with cystic change and partial solid growth of glandular structures with clear cells.
  • The tumor cells had mild cellular atypia, but the tumor lacked papillary growth and a fibrous capsule.
  • Immunohistochemistry was positive for cytokeratins, epithelial membrane antigen, MUC1, MUC4 and MUC6, but negative for myoepithelial markers, MUC2, MUC5AC and MUC5B.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Humans. Immunohistochemistry. Male. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705774.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


11. Xu J, Zhang S, You C, Wang X, Zhou Q: Microvascular density and vascular endothelial growth factor have little correlation with prognosis of craniopharyngioma. Surg Neurol; 2006;66 Suppl 1:S30-4
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Craniopharyngioma is histologically a benign epithelial tumor located in the supersellar cistern that often presents aggressive growth and repeated recurrence.
  • METHODS: The cohorts consisted of 32 patients with AE and 31 patients with SP tumor.
  • CONCLUSIONS: Microvascular density and VEGF in craniopharyngioma tissue have no correlation with prognosis of the tumor, which may be explained by the minimal blood circulation in the craniopharyngioma.
  • Adamantine epithelioma showed more tendency to recur than SP.
  • [MeSH-major] Craniopharyngioma / blood supply. Craniopharyngioma / metabolism. Neoplasm Recurrence, Local / etiology. Pituitary Neoplasms / blood supply. Pituitary Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16904996.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


12. Zhou L, Luo L, Hui X, Chen H, Yu B, Guo G, You C: Primary Rathke's cleft cyst in the cerebellopontine angle associated with apoplexy. Childs Nerv Syst; 2010 Dec;26(12):1813-7
MedlinePlus Health Information. consumer health - Stroke.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rathke's cleft cyst (RCC) is a congenital, benign, epithelial tumor and mainly occurs in sellar region and occasionally in suprasellar region; ectopic RCC is exceedingly rare.
  • The patient underwent the total tumor removal via the retrosigmoid approach with a good recovery.

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20717684.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


13. Ozcan C, Apa DD, Vayisoglu Y, Görür K: Unilateral parotid gland involvement with synchronous multiple Basal cell adenomas. J Craniofac Surg; 2007 Nov;18(6):1470-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Basal cell adenoma (BCA) is a rare benign epithelial tumor of the salivary gland.
  • Salivary gland tumors are observed as single tumors in one salivary gland.
  • Double or multiple tumors of the salivary gland tumors are unusual and metachronous or bilateral salivary gland tumors are more observed than synchronous or unilateral tumors.
  • The most commonly seen multiple tumor unilaterally or bilaterally is the Warthin's tumor.
  • More extensive excision of the parotid gland tumor, careful macroscopic perioperative examination of the surgical specimen, and histologic evaluation of all surgical specimens might be necessary for reducing revision operations and surgical complications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17993904.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Takehara K, Miyamoto K, Kawakami Y, Kumagai M, Samura O, Egawa M, Nakamura H, Mizunoe T, Taniyama K, Saji F: Epigenetic alteration of BRCA1 in human ovarian tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e16532

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic alteration of BRCA1 in human ovarian tumors.
  • The epigenetic alteration of BRCA1 and its contribution in sporadic ovarian tumors are not fully understood.
  • METHODS: We evaluated the DNA methylation status of the BRCA1 5' CpG island by methylation-specific PCR in 12 human ovarian cancer cell lines and 39 primary epithelial ovarian tumor specimens.
  • Cases included the following: malignant (n = 16), borderline (n = 8), and benign (n = 16) tumors.
  • RESULTS: BRCA1 was hypermethylated in one of 12 (8%) ovarian cancer cell lines and 15 of 39 (38%) primary ovarian tumors.
  • Relative to clinicopathological features, BRCA1 methylation was detected in 39% of malignant and borderline tumors and in 38% of benign tumors, suggesting the importance of BRCA1 pathway in both types of tumors.
  • CONCLUSIONS: BRCA1 was found to be frequently hypermethylated both in benign and malignant ovarian tumors.
  • Our results suggest that epigenetic alteration of BRCA1 might play a role in the development of benign and malignant sporadic ovarian tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960779.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Alaoui-Jamali MA Sr, Gupta A, Szarek WA, Bismar TA, Gheorghe R, Schipper HM: A novel selective therapeutic targeting heme oxygenase-1 revealed a potent antimetastatic activity in androgen-refractory human prostate cancer models. J Clin Oncol; 2009 May 20;27(15_suppl):e16090

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we identified heme oxygenase 1 (HO-1) to be significantly upregulated in epithelial PCA cells, but not in surrounding stromal cells, from hormone refractory prostate cancer cases compared to hormone-responsive prostate cancer and to benign tissues.
  • Specifically, inhibition of HO-1 gene in androgen-independent and highly invasive prostate cancer cells, PC3M, decreased HO-1 activity, oxidative stress, MAPKs activation, cell proliferation, and cell migration and invasion in vitro, as well as inhibition of prostate tumor growth and lymph nodes and lung metastases in vivo.
  • OB-24 selectively downregulates HO-1 activity, oxidative stress, and significantly inhibits cell proliferation in vitro and tumor growth and lymph node/lung metastases in vivo.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963085.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Buess M, Rajski M, Vogel B, Herrmann R, Rochlitz C: Tumor endothelial interaction, CD44+/CD24- stem cell signature, and prognosis in early-stage breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):503

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor endothelial interaction, CD44+/CD24- stem cell signature, and prognosis in early-stage breast cancer.
  • : 503 Background: The effects of tumor-endothelial interaction on global gene expression in breast cancer are not yet well characterized.
  • We hypothesized that gene expression signatures induced by tumor-endothelial interaction might be of clinical relevance.
  • METHODS: To this aim we set up an ex vivo co-culture model with human benign and a panel of 6 malignant breast epithelial cells in combination with human venous and microvascular endothelial cells and determined associated gene expression changes with cDNA microarrays.
  • RESULTS: The most prominent response to co-culture was the induction of a set of "M-phase cell cycle" genes in a subset of breast cancer co-cultures, which were absent in co-cultures with normal breast epithelial cells.
  • While in monoculture tumor cells containing the stem cell like CD44+/CD24- signature showed a lower expression of the "M-phase cell cycle" genes than the CD44-/CD24+ cells, in the co-cultures with CD44+/CD24- cells these genes were induced.
  • Interestingly, these tumor cells co- expressed a set of angiogenic factors such as VEGF, PTN, and FGF12 mRNA at significantly higher levels.
  • In vivo, the expression of the gene set derived from the co-culture was remarkably coherent providing a basis for segregation of tumors into two groups.
  • In a univariate analysis, early stage tumors with high expression levels (n= 137) of "M-phase cell cycle" genes had a significantly lower distant metastasis-free survival (p=1.8e-5) (50 % at 10 years) and overall survival rate (p= 5e-9) (52 % at 10 years) than tumors with low expression levels (n= 158) (metastasis-free survival: 73 %; overall survival: 84 % at 10 years).
  • CONCLUSIONS: Our results suggest that the interaction of tumor cells expressing the CD44+/CD24- stem cell like signature, implicating a low proliferative potential, with endothelial cells might explain the unexpected and paradoxical association of the CD44+/CD24- signature with highly proliferative tumors with an unfavorable prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960783.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Chen L, Homesley HD, Scribner DR Jr, Cantuaria GH, He Q, Cheek RL, Whitehead CM, Doobay H, Fischer TJ: Performance of a biomarker panel to identify malignancy within a pelvic mass population. J Clin Oncol; 2009 May 20;27(15_suppl):5566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Performance of a biomarker panel to identify malignancy within a pelvic mass population.
  • In this study, we evaluated the performance of a subset of these markers in differentiating ovarian cancer from benign pelvic mass.
  • METHODS: Pre-operative serum samples were prospectively collected from 254 patients undergoing surgical evaluation for differential diagnosis of a pelvic mass.
  • Pathology showed 76 cases of epithelial ovarian carcinoma (EOC), 17 borderline tumors, 11 other gynecologic cancers, and 150 benign masses.
  • 18 (23.7%) of the EOC patients had stage I tumors; 6 (7.9%) stage II; 44 (57.9%) stage III; and 8 (10.5%) stage IV.
  • All calculations compared the benign vs. EOC and borderline tumor populations.
  • The combination of CA125, HE4 and glycodelin exhibited the highest overall performance in identifying malignancy from benign masses, demonstrating 80% sensitivity, 80% specificity in patients <55 years, and 89% sensitivity, 80% specificity in patients ≥55.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962561.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Calcaterra R, Franco G, Valenzano M, Fazio R, Morrone A: Clinical features and treatment of dermatosis papulosa nigra in migrants to Italy. Skinmed; 2010 Jul-Aug;8(4):207-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dermatosis papulosa nigra (DPN) is a benign epithelial tumor that is common in dark-skinned people.
  • Therefore, even if DPN is a benign disease, the lesions are unaesthetic and the therapeutic options are quite inefficient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21137605.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Ishida M, Hotta M, Tsukamura A, Taga T, Kato H, Ohta S, Takeuchi Y, Nakasu S, Okabe H: Malignant transformation in craniopharyngioma after radiation therapy: a case report and review of the literature. Clin Neuropathol; 2010 Jan-Feb;29(1):2-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Craniopharyngioma is a benign epithelial tumor that is thought to arise from the remnant of the Rathke pouch.
  • MATERIALS AND METHODS: Histopathological and immunohistochemical analyses were carried out for specimens of the suprasellar tumor (from three resections, with the third surgery performed after radiation therapy).
  • RESULTS: The resected tumors from the first and second surgeries comprised islands of loosely cohesive aggregates of epithelial cells, so-called stellate reticulum.
  • At the periphery of the nests, palisaded columnar epithelium was observed.
  • Immunohistochemical studies revealed that the p53 protein was over-expressed in the malignant component, whereas its expression was much lower in the benign component.

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040326.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 17
  •  go-up   go-down


20. Evans PM, Lynch GL, Dubielzig RR: Anterior uveal spindle cell tumor in a cat. Vet Ophthalmol; 2010 Nov;13(6):387-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anterior uveal spindle cell tumor in a cat.
  • PURPOSE: To describe a case of anterior uveal spindle cell tumor in a cat with features similar to spindle cell tumor of blue eyed dogs.
  • A diagnosis of a benign epithelial tumor was suggested by a FNA of the mass.
  • The cells were arranged in streams and bundles and exhibited Antoni-A and Antoni-B tissue patterns, which are characteristic of Schwann cell tumors.
  • CONCLUSIONS: Based on its histopathologic characteristics, this iris tumor was diagnosed as a Schwann cell variant of a peripheral nerve sheath tumor (PNST) closely resembling the spindle cell tumor of blue-eyed dogs.
  • [MeSH-major] Cat Diseases / pathology. Uveal Neoplasms / veterinary

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American College of Veterinary Ophthalmologists.
  • (PMID = 21182724.001).
  • [ISSN] 1463-5224
  • [Journal-full-title] Veterinary ophthalmology
  • [ISO-abbreviation] Vet Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Reichart PA, Jundt G: [Benign epithelial odontogenic tumors]. Pathologe; 2008 May;29(3):175-6, 178-88

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign epithelial odontogenic tumors].
  • The group of benign epithelial odontogenic tumors consists of the four member types of the ameloblastoma family (solid/multicystic, extraosseous/peripheral, desmoplastic, unicystic), squamous odontogenic tumors, calcifying odontogenic tumors, adenomatoid odontogenic tumors, and keratocystic odontogenic tumors, the former "keratocysts" that were recently reclassified by the World Health Organization and are now regarded as tumors.
  • The latter are by far the most frequent tumors in this group, followed by solid/multicystic ameloblastoma.
  • Although the etiology of these lesions is still unknown, a close relationship to normal tooth development is obvious, which is partially imitated by some tumors.
  • [MeSH-major] Jaw Neoplasms / pathology. Odontogenic Cyst, Calcifying / pathology. Odontogenic Tumor, Squamous / pathology. Odontoma / pathology
  • [MeSH-minor] Ameloblastoma / classification. Ameloblastoma / pathology. Ameloblastoma / surgery. Cementoma / classification. Cementoma / pathology. Cementoma / surgery. Diagnosis, Differential. Humans. Jaw / pathology. Jaw / surgery. Prognosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18389236.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] Adenoameloblastoma
  •  go-up   go-down


22. Furusato B, Shaheduzzaman S, Petrovics G, Dobi A, Seifert M, Ravindranath L, Nau ME, Werner T, Vahey M, McLeod DG, Srivastava S, Sesterhenn IA: Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens. Prostate Cancer Prostatic Dis; 2008;11(2):194-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens.
  • Furthermore, to increase the sample quality, we utilized laser capture microdissection of prostate tumor and benign epithelial cells.
  • [MeSH-major] Adenocarcinoma / genetics. Epithelial Cells / metabolism. Gene Expression Profiling. Neoplasm Proteins / genetics. Prostate / metabolism. Prostatic Neoplasms / genetics. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Tissue Preservation / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17768422.001).
  • [ISSN] 1476-5608
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


23. Yakoushina TV, Morotti RA, Strauchen JA, Unger PD: Renal benign epithelial nodal inclusions. Ann Diagn Pathol; 2008 Jun;12(3):181-6
MedlinePlus Health Information. consumer health - Kidney Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal benign epithelial nodal inclusions.
  • There are 3 case series reports describing benign epithelial inclusions in nodal sinuses of perinephric lymph nodes of pediatric patients.
  • The majority of these inclusions were observed in perinephric lymph nodes removed during nephrectomies from pediatric patients with Wilms' tumors.
  • We report 2 cases of benign renal tubular epithelial inclusions located in the perinephric hilar lymph nodes.
  • One of our cases is, to our knowledge, the first case of benign renal epithelial inclusions reported in an adult patient.
  • [MeSH-major] Epithelial Cells / pathology. Inclusion Bodies / pathology. Kidney Diseases / pathology. Kidney Tubules / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Biomarkers / metabolism. Child, Preschool. Female. Humans. Hydronephrosis / pathology. Immunohistochemistry. Kidney Neoplasms / pathology. Male. Nephrectomy. Pyelonephritis / pathology. Retrospective Studies. Wilms Tumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486893.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


24. Park HS, Kim SH, Kim SH, Paik JH, Hwang SI, Jung SI, Choi YH: Benign mixed epithelial and stromal tumor of the kidney: imaging findings. J Comput Assist Tomogr; 2005 Nov-Dec;29(6):786-9
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign mixed epithelial and stromal tumor of the kidney: imaging findings.
  • Three cases of mixed epithelial and stromal tumor of the kidney with their imaging findings are described; these cases have not been reported previously in the radiology literature.
  • This benign tumor contains epithelial and spindle cell stromal components and arises exclusively in adult women.
  • [MeSH-major] Kidney / pathology. Kidney / radiography. Kidney Neoplasms / diagnosis. Neoplasms, Complex and Mixed / diagnosis. Neoplasms, Glandular and Epithelial / diagnosis. Stromal Cells / pathology
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Rare Diseases. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16272852.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Rosner IL, Ravindranath L, Furusato B, Chen Y, Gao C, Cullen J, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G: Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy. Urology; 2007 Dec;70(6):1225-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
  • Because AR mutations or amplification are rare in early stage CaP, we hypothesized that altered AR expression in prostate tumor cells may provide a prognostic indicator of disease progression.
  • METHODS: RNA from laser capture microdissected (LCM) tumor and benign epithelial cells from radical prostatectomy specimens of 115 hormone-naive patients were studied.
  • A ratio of the expression of AR gene, normalized to GAPDH gene expression in the same specimens, was compared in tumor and benign epithelial cells (tumor-to-benign ratio) and correlated with clinicopathologic features.
  • RESULTS: Paired t test analysis revealed a 62% lower AR expression in tumor tissue compared with benign tissue (P = 0.0005).
  • However, multivariate Cox proportional hazards regression analysis of time to PSA recurrence revealed that higher tumor cell associated AR expression (continuous, log-transformed), significantly increases odds of prostate-specific antigen (PSA) recurrence (P = 0.0139) when controlling for age at surgery, race, time from diagnosis to surgery, risk stratification, pathologic T stage, Gleason sum, and margin status.
  • CONCLUSIONS: Quantitative determination of AR gene expression levels in prostate epithelial cells may be useful for predicting PSA recurrence.


26. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG, Moon WS: Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology; 2009;41(4):366-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic significance of SIRT1 in ovarian epithelial tumours.
  • Therefore, we investigated the prevalence and the prognostic impact of SIRT1 and p53 expression in ovarian epithelial tumours.
  • METHODS: Immunohistochemical expression of SIRT1 and p53 were evaluated using tissue microarray in 40 cases of benign epithelial tumours, 36 cases of borderline tumours, and 90 cases of malignant tumours.
  • RESULTS: Expression of SIRT1 was significantly increased in malignant epithelial tumours compared to benign and borderline epithelial tumours (p < 0.001).
  • Despite the frequent expression of SIRT1 in malignant ovarian epithelial tumours, serous carcinomas of high FIGO stage showed less frequent SIRT1 expression compared to that of low stage serous carcinomas (p = 0.029).
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Sirtuins / biosynthesis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Prognosis. Sirtuin 1. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404850.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins
  •  go-up   go-down


27. Szporek BJ, Cieślik T, Jedrzejewski PW, Lipiarz LZ: [Calcifying epithelial odontogenic tumor (Pindborg tumor)]. Wiad Lek; 2005;58(7-8):458-61
Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Calcifying epithelial odontogenic tumor (Pindborg tumor)].
  • The calcifying epithelial odontogenic tumor (CEOT) is a rare benign odontogenic neoplasm which was first described by Pindborg in 1955 representing only 1% of all odontogenic tumors.
  • The tumor has an ectodermal odontogenic origin.
  • This tumor are considered benign but can be locally aggressive in nature with recurrence rates of 10-15% reported.
  • Since 1973 three cases only of the Pinborg tumor have been presented in the Polish literature.
  • We described the case of a 44-year-old man with Pindborg tumor in the right maxilla.
  • Standard x-ray examinations and CT scan were performed in order to obtain information about tumor's localization.
  • Autors discuss the radiologic features of calcifying epithelial odontogenic tumor and treatment method and the relevant literature.
  • [MeSH-major] Calcinosis / diagnosis. Maxillary Neoplasms / diagnosis. Odontogenic Tumors / diagnosis
  • [MeSH-minor] Adult. Humans. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425804.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


28. Compérat E, Couturier J, Peyromaure M, Cornud F, Vieillefond A: Benign mixed epithelial and stromal tumor of the kidney (MEST) with cytogenetic alteration. Pathol Res Pract; 2005;200(11-12):865-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign mixed epithelial and stromal tumor of the kidney (MEST) with cytogenetic alteration.
  • Benign mixed epithelial and stromal tumor of the kidney (MEST) is a new, rare entity.
  • These tumors are composed of two components: a stromal and an epithelial one.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Kidney Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Neoplasms, Glandular and Epithelial / pathology. Translocation, Genetic
  • [MeSH-minor] Actins / analysis. Adult. Biomarkers, Tumor / analysis. Carcinoma, Renal Cell / diagnosis. Cysts / pathology. Desmin / analysis. Diagnosis, Differential. Humans. Keratins / analysis. Male. Nephrectomy. Stromal Cells / chemistry. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792135.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Desmin; 68238-35-7 / Keratins
  •  go-up   go-down


29. Sedghizadeh PP, Wong D, Shuler CF, Linz V, Kalmar JR, Allen CM: Multifocal calcifying epithelial odontogenic tumor. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Aug;104(2):e30-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal calcifying epithelial odontogenic tumor.
  • The calcifying epithelial odontogenic tumor (CEOT), or Pindborg tumor, is a rare and benign odontogenic neoplasm that affects the jaw.
  • In this article, we present a unique case of CEOT affecting multiple sites in the maxilla and mandible of a 51-year-old white man.
  • [MeSH-major] Jaw Neoplasms / pathology. Odontogenic Tumors / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Rare Diseases

  • Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17630096.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Zhang SL, Yu Y, Jiang T, Lin B, Gao H: [Expression and significance of KiSS-1 and its receptor GPR54 mRNA in epithelial ovarian cancer]. Zhonghua Fu Chan Ke Za Zhi; 2005 Oct;40(10):689-92
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of KiSS-1 and its receptor GPR54 mRNA in epithelial ovarian cancer].
  • OBJECTIVE: To study the expression and significance of metastasis suppressor gene KiSS-1 and its receptor GPR54 in epithelial ovarian cancer.
  • METHOD: The expression and their clinical significance of KiSS-1 and GPR54 were evaluated by RT-PCR in 37 patients with epithelial ovarian cancer, 15 patients with borderline epithelial ovarian tumors, 15 patients with epithelial benign tumors and 11 patients with normal ovarian tissues.
  • RESULTS: The positivity and relative contents of KiSS-1 mRNA in patients with epithelial ovarian cancer (68%, 0.82 +/- 0.09) and borderline epithelial ovarian tumors (60%, 0.80 +/- 0.10) were all higher than in patients with epithelial benign tumor (20%, 0.65 +/- 0.10) and normal ovarian tissues (18%, 0.66 +/- 0.06; P < 0.05).
  • The positivity and relative contents of KiSS-1 mRNA in patients with epithelial ovarian cancer correlated with their clinical stage and lymph node metastasis (P < 0.05).
  • There was no difference in the positivity and relative contents of GPR54 mRNA between patients with epithelial ovarian cancer (70%, 0.79 +/- 0.07), borderline epithelial ovarian tumor (67%, 0.76 +/- 0.10), benign epithelial ovarian tumor (60%, 0.73 +/- 0.07) and normal ovarian tissues (45%, 0.78 +/- 0.08), respectively (all P > 0.05).
  • The positivity and relative contents of GPR54 mRNA in patients with epithelial ovarian cancer did not correlate with their clinical stage, histology grade, lymph node metastasis and production of ascites (P > 0.05).
  • CONCLUSION: KiSS-1 and GPR54 may play an important role in inhibiting the invasion and metastasis of early epithelial ovarian cancer.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / pathology. Receptors, G-Protein-Coupled / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Female. Humans. Kisspeptins. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16277902.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / KISS1 protein, human; 0 / KISS1R protein, human; 0 / Kisspeptins; 0 / RNA, Messenger; 0 / Receptors, G-Protein-Coupled; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


31. Krajewska M, Olson AH, Mercola D, Reed JC, Krajewski S: Claudin-1 immunohistochemistry for distinguishing malignant from benign epithelial lesions of prostate. Prostate; 2007 Jun 15;67(9):907-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin-1 immunohistochemistry for distinguishing malignant from benign epithelial lesions of prostate.
  • BACKGROUND: Claudins are a family of approximately 23 integral membrane tight junction (TJ) proteins that maintain cell polarity and paracellular barrier functions in epithelial and endothelial cells.
  • METHODS: Using immunohistochemistry, the expression of Claudin-1 was investigated in prostate tissue samples arranged in a tissue microarray (TMA) format and comprising elements of normal prostatic epithelium (n = 6), benign prostatic hyperplasia (BPH; n = 38), prostatic intraepithelial neoplasia (PIN; n = 11), and prostate adenocarcinoma (n = 48).
  • RESULTS: In benign prostatic epithelium, pronounced Claudin-1 expression was observed in the basal cell layer with no staining in luminal cells.
  • Prostate adenocarcinoma specimens from 98% (47/48) patients lacked Claudin-1 immunostaining, and no cases contained >5% immunopositive tumor cells.
  • CONCLUSIONS: Claudin-1 immunohistochemistry should be considered for use as a new diagnostic tool for distinguishing malignant from benign lesions of the prostate.

  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17440968.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA114810; United States / NCI NIH HHS / CA / CA114810-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / CLDN1 protein, human; 0 / Claudin-1; 0 / Membrane Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


32. Kim SH, Miller FR, Tait L, Zheng J, Novak RF: Proteomic and phosphoproteomic alterations in benign, premalignant and tumor human breast epithelial cells and xenograft lesions: biomarkers of progression. Int J Cancer; 2009 Jun 15;124(12):2813-28
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic and phosphoproteomic alterations in benign, premalignant and tumor human breast epithelial cells and xenograft lesions: biomarkers of progression.
  • The MCF10A human breast epithelial cell lineage includes the benign MCF10A cells, premalignant cells (MCF10AT, MCF10ATG3B) and malignant MCF10CA1a tumor cells.
  • The premalignant and tumor cells recapitulate the progressive alterations associated with the temporal development of PBD and carcinoma.
  • K-Ras was not detected, N-Ras levels were unchanged; Rac and Rho levels increased in 10CA1a tumor cells.
  • Phospho-phosphatidylinositol 3-kinase, phosphoinositide-dependent protein kinase 1 (PDK1), phospho-PDK1, phospho-eukaryotic translation initiation factor 4E (eIF4E) and phospho-eukaryotic initiation factor 4E binding protein 1 (4E-BP1) levels progressively increased in the cell lineage, with the greatest increase monitored in 10CA1a tumor cells.
  • Immunohistochemistry confirmed Ras, phospho-Akt and phospho-p70S6K (Thr 421/ Ser 424) expression in lesions arising from premalignant and tumor cells.
  • FOXO 1, phospho-FOXO 1 and phospho-FOXO 4 were significantly elevated in 10ATG3B premalignant and 10CA1a tumor cells.
  • Phospho-FOXO 3a was progressively elevated, with the greatest levels detected in 10CA1a tumor cells.
  • Immunohistochemistry revealed that phospho-FOXO 1, 3a and 4 staining was less in benign lesions, but elevated in advanced 10ATG3B and malignant 10CA1a lesions, showing a correspondence between the cells and lesions.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 UICC.
  • [Cites] Am J Pathol. 1996 Jan;148(1):313-9 [8546221.001]
  • [Cites] EMBO J. 1996 Dec 2;15(23):6541-51 [8978681.001]
  • [Cites] Science. 1998 Nov 13;282(5392):1318-21 [9812896.001]
  • [Cites] Genes Dev. 1997 Mar 15;11(6):701-13 [9087425.001]
  • [Cites] FEBS Lett. 1997 Jun 23;410(1):78-82 [9247127.001]
  • [Cites] Science. 1998 Jan 30;279(5351):707-10 [9445476.001]
  • [Cites] Genes Dev. 1998 Feb 15;12(4):502-13 [9472019.001]
  • [Cites] J Biol Chem. 1998 Sep 11;273(37):24052-6 [9727023.001]
  • [Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4240-5 [10200246.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1474-81 [10334533.001]
  • [Cites] J Biol Chem. 1999 Jun 11;274(24):16741-6 [10358014.001]
  • [Cites] J Biol Chem. 1999 Jun 11;274(24):17164-70 [10358073.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1422-37 [10364159.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7421-6 [10377430.001]
  • [Cites] Biochem J. 2005 Jan 15;385(Pt 2):399-408 [15456405.001]
  • [Cites] Mol Cancer Ther. 2005 Feb;4(2):271-9 [15713898.001]
  • [Cites] Mol Cancer Ther. 2005 Jun;4(6):977-86 [15956255.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4338-40 [15958615.001]
  • [Cites] Oncogene. 2008 Apr 7;27(16):2258-62 [18391968.001]
  • [Cites] Oncogene. 2003 Nov 6;22(50):8205-11 [14603261.001]
  • [Cites] J Mol Med (Berl). 1999 Sep;77(9):656-65 [10569203.001]
  • [Cites] Biochem J. 1999 Dec 1;344 Pt 2:427-31 [10567225.001]
  • [Cites] Exp Cell Res. 1999 Nov 25;253(1):100-9 [10579915.001]
  • [Cites] EMBO J. 2000 Jun 1;19(11):2393-8 [10835338.001]
  • [Cites] Cell. 2000 Oct 13;103(2):185-8 [11057891.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):39223-30 [11010972.001]
  • [Cites] Nat Cell Biol. 2001 Mar;3(3):245-52 [11231573.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jan;65(2):101-10 [11261825.001]
  • [Cites] J Biol Chem. 2001 May 11;276(19):15609-15 [11278702.001]
  • [Cites] J Natl Cancer Inst. 2001 May 16;93(10):776-82 [11353788.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):5985-91 [11507039.001]
  • [Cites] Science. 2001 Nov 2;294(5544):1102-5 [11691993.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):148-54 [11857399.001]
  • [Cites] Science. 2002 May 31;296(5573):1655-7 [12040186.001]
  • [Cites] Mol Cell. 2002 Jul;10(1):151-62 [12150915.001]
  • [Cites] Nat Cell Biol. 2002 Sep;4(9):648-57 [12172553.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3512-9 [12429642.001]
  • [Cites] Toxicol Sci. 2003 Sep;75(1):74-81 [12805649.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Cell. 2004 Apr 16;117(2):225-37 [15084260.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4394-9 [15231645.001]
  • [Cites] N Engl J Med. 1985 Jan 17;312(3):146-51 [3965932.001]
  • [Cites] Cancer Res. 1987 Oct 15;47(20):5290-3 [3308076.001]
  • [Cites] Int J Cancer. 1989 Mar 15;43(3):431-5 [2784420.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8212-6 [2122455.001]
  • [Cites] Cell. 1992 Aug 7;70(3):389-99 [1643657.001]
  • [Cites] Cell. 1992 Aug 7;70(3):401-10 [1643658.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 3;85(21):1725-32 [8411256.001]
  • [Cites] Nature. 1994 Aug 18;370(6490):527-32 [8052307.001]
  • [Cites] Nature. 1994 Oct 27;371(6500):762-7 [7935836.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5744-8 [7777579.001]
  • [Cites] Breast Cancer Res Treat. 1995 Jul;35(1):133-44 [7612899.001]
  • [Cites] Nature. 1995 Aug 17;376(6541):599-602 [7637810.001]
  • [Cites] Oncogene. 1995 Oct 19;11(8):1639-47 [7478589.001]
  • [Cites] Genes Dev. 1998 Nov 15;12(22):3499-511 [9832503.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15587-91 [9861013.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15653-8 [9861025.001]
  • (PMID = 19291795.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES10595; United States / NIEHS NIH HHS / ES / R01 ES010595-05; United States / NIEHS NIH HHS / ES / P30 ES006639-14; United States / NIEHS NIH HHS / ES / P30 ES06639; United States / NIEHS NIH HHS / ES / P30 ES006639; United States / NIEHS NIH HHS / ES / R01 ES010595
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Forkhead Transcription Factors; 0 / FoxO3 protein, mouse; 0 / FoxO4 protein, mouse; 0 / Foxo1 protein, mouse; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS137631; NLM/ PMC4123863
  •  go-up   go-down


33. Reichart PA, Jundt G: [Benign "mixed" odontogenic tumors]. Pathologe; 2008 May;29(3):189-98

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign "mixed" odontogenic tumors].
  • Benign "mixed"odontogenic tumors consist of an epithelial and ectomesenchymal tumor component, distinguishing them from pure epithelial and pure ectomesenchymal odontogenic tumors.
  • Therefore, they can sometimes already be differentiated radiologically from epithelial odontogenic tumors.
  • Some of the mixed odontogenic lesions are regarded as true tumors (ameloblastic fibroma, odontoameloblastoma, dentinogenic ghost cell tumor), while others are assumed to represent hamartomatous lesions (complex and compound odontoma, probably also ameloblastic fibrodentinoma and ameloblastic fibroodontoma).
  • Preceded by keratocystic odontogenic tumor, complex and compound odontomas are the second most common odontogenic tumors, while other members of the "mixed" odontogenic tumor group are far less frequently diagnosed.
  • Odontoameloblastoma and dentinogenic ghost cell tumors are locally aggressive lesions that require total resection.
  • [MeSH-major] Jaw Neoplasms / pathology. Mixed Tumor, Malignant / pathology. Odontogenic Tumors / pathology
  • [MeSH-minor] Dental Cementum / pathology. Dental Enamel / pathology. Dentin / pathology. Humans. Jaw / pathology. Jaw / surgery. Odontodysplasia / pathology. Odontodysplasia / surgery. Odontoma / classification. Odontoma / pathology. Odontoma / surgery. Precancerous Conditions / classification. Precancerous Conditions / pathology. Precancerous Conditions / surgery. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18369623.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


34. Zhou JW, Gan NY, Zhang WJ: [The expression of MKP-1 and p-ERK(1/2) in primary ovarian epithelial tumor tissues]. Fen Zi Xi Bao Sheng Wu Xue Bao; 2009 Jun;42(3-4):224-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expression of MKP-1 and p-ERK(1/2) in primary ovarian epithelial tumor tissues].
  • To investigate the expression of mitogen activated protein kinase phosphatase-1 (MKP-1) and phosphorylation extracellular signal-regulated kinases (p-ERK(1/2)) in primary ovarian epithelial tumor tissues, and provide experiment's foundation on the new treatment in ovarian cancer.
  • Expression of MKP-1 and p-ERK(1/2) in tissues from 64 patients with primary ovarian epithelial tumor, 35 patients with ovarian epithelial bordline tumor, 32 patients with ovarian epithelial benign tumor and 26 normal ovarian tissues was detected by immunohistochemistry.
  • Immunohistochemistry and Western-blot assay showed that the expression of MKP-1 was gradually decreased in normal ovarian tissues, benign tumor, bordline tumor and carcinoma respectively, and there were significant differences among them (P < 0.01).
  • However, the expression of p-ERK(1/2) was gradually increased in normal ovarian tissues, benign tumor, bordline tumor and carcinoma respectively, and there were also significant differences among them (P < 0.01), the p-ERK(1/2) expression level in the carcinoma tissues of stage III/IV patients was significantly higher than that of stage I/II patients.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697705.001).
  • [ISSN] 1673-520X
  • [Journal-full-title] Fen zi xi bao sheng wu xue bao = Journal of molecular cell biology
  • [ISO-abbreviation] Fen Zi Xi Bao Sheng Wu Xue Bao
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.1.3.48 / Dual Specificity Phosphatase 1
  •  go-up   go-down


35. Zagorianakou N, Stefanou D, Makrydimas G, Zagorianakou P, Briasoulis E, Karavasilis V, Pavlidis N, Agnantis NJ: Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors. Histol Histopathol; 2006 04;21(4):341-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors.
  • MT expression in human tumors has been linked to resistance to anticancer drugs and differentiation and progression in some types of tumors.
  • This study examined the immunohistochemical expression of MTs in benign, borderline and malignant tumors of ovarian surface epithelium and the possible correlations with clinicopathological parameters and survival.
  • A total of 87 cases with diagnosis of ovarian surface epithelial tumors were included.
  • Specifically, 21 cases of benign cystadenomas (11 serous and 10 mucinous), 14 borderline (low malignant potential tumors, 8 mucinous and 6 serous) and 52 cases of ovarian cancer were analysed.
  • Immunohistochemical expression of MT (cut-off level > 10% of tumor cells) was clearly associated with malignancy.
  • A statistically significant correlation was found between the expression of MT in cancer cases and benign tumors (p < 0.0001) and cancer cases and borderline tumors p = 0.003.
  • MT constitutes a marker that characterizes aggressiveness and a high malignant potential in ovarian epithelial tumors.
  • In diagnostic problems MT may help distinguish between benign, borderline and malignant tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cell Differentiation / genetics. Cell Proliferation. Cystadenoma, Mucinous / chemistry. Cystadenoma, Mucinous / diagnosis. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / chemistry. Cystadenoma, Serous / diagnosis. Cystadenoma, Serous / pathology. Diagnosis, Differential. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437378.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; 9038-94-2 / Metallothionein
  •  go-up   go-down


36. Thyavihally YB, Tongaonkar HB, Desai SB: Benign mixed epithelial stromal tumor of the renal pelvis with exophytic growth: case report. Int Semin Surg Oncol; 2005 Sep 9;2:18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign mixed epithelial stromal tumor of the renal pelvis with exophytic growth: case report.
  • BACKGROUND: Mixed epithelial and stromal tumor (MEST) is a distinctive benign composite neoplasm of the kidney predominantly seen in females mostly in the perimenopausal period.
  • Although these tumors are known to arise from renal pelvis, our case was distinct in that it had no intrapelvic component growing in exophytic fashion.
  • Microscopically, the tumor was composed of large collagenized areas containing bundles of spindle cells and several 'microcysts' lined by cuboidal epithelium suggestive of a benign mixed epithelial stromal tumor.
  • DISCUSSION: Mixed epithelial tumors usually present in perimenopausal women as a partially cystic mass.
  • Tumors are composed of irregular mixtures of cystic and solid areas, glands with variable complexity and distribution and the stromal component is characterized by a spindle cell proliferation.
  • Commonly, it arises from the renal parenchyma and pelvis and nephrectomy is advocated to manage these tumors.
  • CONCLUSION: MEST is a distinctive benign tumor of the kidney that should be distinguished from other renal neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2004 Dec;5(12):747-9 [15581546.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):958-70 [10895818.001]
  • [Cites] Hum Pathol. 2001 May;32(5):513-20 [11381370.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):700-2 [11764393.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):2-20 [9503503.001]
  • [Cites] Hinyokika Kiyo. 2004 Jan;50(1):49-52 [15032017.001]
  • [Cites] Pathologe. 2004 Sep;25(5):356-61 [15127227.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):359-67 [15322873.001]
  • [Cites] Pathol Res Pract. 1998;194(6):445-8 [9689654.001]
  • [Cites] Adv Anat Pathol. 2003 Jul;10(4):223-33 [12826829.001]
  • (PMID = 16150156.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1215508
  •  go-up   go-down


37. Jordan SJ, Green AC, Whiteman DC, Webb PM: Risk factors for benign serous and mucinous epithelial ovarian tumors. Obstet Gynecol; 2007 Mar;109(3):647-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for benign serous and mucinous epithelial ovarian tumors.
  • OBJECTIVE: To investigate the risk factors for benign serous and mucinous epithelial ovarian tumors.
  • METHODS: Cases were women newly diagnosed with benign serous ovarian tumors (n=230) or benign mucinous tumors (n=133) between 2002 and 2005.
  • RESULTS: Current smoking was associated with a three-fold increase in risk of benign mucinous tumors (OR 3.25, 95% CI 1.97-5.34), and there was a trend of increasing risk with increasing amount smoked (P<.001).
  • Both recent obesity (OR 1.93, 95% CI 1.30-2.88) and obesity at age 20 (OR 4.38, 95% CI 1.88-10.20) were associated with increased risk of benign serous ovarian tumors, and having had a hysterectomy was also related to increased risk of serous (OR 2.75, 95% CI 1.90-3.96), but not mucinous tumors.
  • Ever having had a term pregnancy was inversely associated with both tumor types (combined OR 0.65, 95% CI 0.43-0.97), although greater numbers of pregnancies did not decrease risk further.
  • CONCLUSION: Our results suggest some differences in risk factors between benign serous and mucinous epithelial ovarian tumors and that risk factors for benign serous tumors differ from those well established for ovarian cancer.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Smoking and Youth.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17329516.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


38. Gopalakrishnan R, Simonton S, Rohrer MD, Koutlas IG: Cystic variant of calcifying epithelial odontogenic tumor. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Dec;102(6):773-7
Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic variant of calcifying epithelial odontogenic tumor.
  • Calcifying epithelial odontogenic tumor (CEOT) is a benign, locally aggressive odontogenic neoplasm characterized by sheets and nests of epithelial cells with deeply eosinophilic or occasionally clear cytoplasm, calcifications, and eosinophilic amorphous material that stains positive for amyloid.
  • [MeSH-major] Maxillary Neoplasms / pathology. Odontogenic Cyst, Calcifying / pathology. Odontogenic Tumors / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17138180.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Kim SH, Zukowski K, Novak RF: Rapamycin effects on mTOR signaling in benign, premalignant and malignant human breast epithelial cells. Anticancer Res; 2009 Apr;29(4):1143-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapamycin effects on mTOR signaling in benign, premalignant and malignant human breast epithelial cells.
  • Rapamycin resistance has been reported in human breast epithelial tumor cells.
  • Rapamycin effects on mTOR signaling and resistance were examined using benign, premalignant and tumor human breast epithelial cells.
  • Rapamycin inhibition of cell proliferation, the cell cycle and mTOR signaling, including p70S6 and S6RP phosphorylation, was most effective in benign (MCF10A) and premalignant (MCF10AT; MCF10ATG3B) human breast epithelial cells, relative to MCF10CA1a tumor cells.
  • Rapamycin resistance was reflected by reduced inhibition of p70S6K and S6RP phosphorylation in MCF10CA1a tumor cells, with RS6P showing the least response to rapamycin in the tumor cells.
  • These data suggest that inhibition of mTOR signaling and STAT3 phosphorylation in benign and premalignant cells may be effective in the treatment of proliferative breast disease (PBD) and in the prevention of tumorigenesis and tumor recurrence.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414357.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / ES10595; United States / NIEHS NIH HHS / ES / P30 ES06639
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / STAT1 Transcription Factor; 0 / STAT1 protein, human; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


40. Guo RX, Qiao YH, Zhou Y, Li LX, Shi HR, Chen KS: Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol Int; 2008 Dec;58(12):749-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer.
  • AKT plays an important role in malignant behavior of tumors.
  • The purpose of the present study was to determine the expression of phosphorylated AKT (P-AKT) and nuclear factor-kappaB (NF-kappaB) p65 and their association with clinicopathological parameters and prognosis in epithelial ovarian tumor.
  • On immunohistochemistry 115 samples of ovarian tissue that included 68 specimens of epithelial ovarian cancer, 12 of borderline tumor, 24 of epithelial benign tumor and 11 of normal ovary, were evaluated.
  • The positive expression rate of P-AKT and NF-kappaB p65 were higher in epithelial ovarian cancer than in normal ovarian tissue (P<0.01).
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Phosphorylation. Prognosis. Survival Rate. Up-Regulation. Young Adult


41. Diaz NM, Vrcel V, Centeno BA, Muro-Cacho C: Modes of benign mechanical transport of breast epithelial cells to axillary lymph nodes. Adv Anat Pathol; 2005 Jan;12(1):7-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modes of benign mechanical transport of breast epithelial cells to axillary lymph nodes.
  • So-called "occult" micrometastases detected by such methods have led to speculation that some may have reached the SLNs by benign mechanical transport (BMT) rather than a metastatic process.
  • We review evidence suggesting two potential modes of BMT: lymphatic transport of epithelial cells displaced by biopsy of the primary breast tumor and by breast massage-assisted SLN localization.
  • The significance of small epithelial clusters in SLNs is currently unknown.
  • [MeSH-major] Breast Neoplasms / pathology. Epithelial Cells / pathology. Lymphatic Metastasis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15614159.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


42. Yang Y, Nie X, Lu J, Lu XY, Wei YY, Wang H, Han ZH, Chen ZH, Zheng J: [Mixed epithelial and stromal tumor of kidney]. Zhonghua Bing Li Xue Za Zhi; 2006 Jan;35(1):29-31
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mixed epithelial and stromal tumor of kidney].
  • OBJECTIVE: To study the clinicopathological features and differential diagnoses of mixed epithelial and stromal tumor of the kidney.
  • METHODS: Clinical and pathological characteristics of 4 cases of mixed epithelial and stromal tumor of the kidney were studied.
  • Grossly the tumors had a solid and cyst appearance.
  • Microscopically, the tumors were composed of a mixture of stromal and epithelial elements.
  • The epithelial elements were variable in cell types including cuboidal, hobnail and columnar cells.
  • One case showed Müllerian and intestinal epithelial differentiations.
  • Stromal elements essentially consisted of spindle cells, with thick-walled blood vessels and bands of smooth muscle cells as distinctive features of the tumor.
  • Immunohistochemical staining revealed that the epithelial components were positive for AE1/AE3, whereas the stromal components were positive for ER, PR, and SMA.
  • CONCLUSIONS: Mixed epithelial and stromal tumor of the kidney is a benign neoplasm with distinct histopathological features.
  • [MeSH-major] Kidney Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Neoplasms, Glandular and Epithelial / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608646.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Actins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


43. Argani P: Metanephric neoplasms: the hyperdifferentiated, benign end of the Wilms tumor spectrum? Clin Lab Med; 2005 Jun;25(2):379-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metanephric neoplasms: the hyperdifferentiated, benign end of the Wilms tumor spectrum?
  • Metanephric neoplasms represent a spectrum of differentiated lesions that seem most likely to be related to Wilms tumor.
  • These neoplasms include a pure stromal lesion, a pure epithelial lesion (MA), and a mixed epithelial-stromal lesion (MAF).
  • The continuity of these lesions with Wilms tumor has been demonstrated best in the epithelial lesions.
  • The relationship of Wilms tumor, MAF with mitoses or combined MA/Wilms tumor lesions, and usual MAF or usual MA may be viewed as analogous to that of neuroblastoma, differentiating neuroblastoma, and ganglioneuroma, in which progressively more mature or differentiated counterparts of malignant embryonal lesions are associated with a greater probability of benign clinical behavior.
  • Such a spectrum already is recognized for cystic ILNR-derived nephroblastic lesions, ranging from cystic Wilms tumor, cystic partially differentiated nephroblastoma, and cystic nephroma.
  • Although this concept implies that the more active lesions (Wilms tumor) mature with time into inactive ones (usual MAFs or MA), the converse (that an active Wilms tumor can arise within an inactive usual MAF or MA) remains possible.
  • [MeSH-major] Kidney Neoplasms / pathology. Wilms Tumor / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15848742.001).
  • [ISSN] 0272-2712
  • [Journal-full-title] Clinics in laboratory medicine
  • [ISO-abbreviation] Clin. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


44. Granowitz EV, Tonomura N, Benson RM, Katz DM, Band V, Makari-Judson GP, Osborne BA: Hyperbaric oxygen inhibits benign and malignant human mammary epithelial cell proliferation. Anticancer Res; 2005 Nov-Dec;25(6B):3833-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperbaric oxygen inhibits benign and malignant human mammary epithelial cell proliferation.
  • Normal mammary epithelia, primary tumor and metastatic tumor cells derived from the same patient and immortalized by transfection with the human papilloma virus E6 oncogene, as well as the MCF7 human mammary adenocarcinoma cell line, were studied.
  • CONCLUSION: HBO inhibits benign and malignant mammary epithelial cell proliferation, but does not enhance cell death.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16312043.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI-02188
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


45. Mukherjee S, Frolova N, Sadlonova A, Novak Z, Steg A, Page GP, Welch DR, Lobo-Ruppert SM, Ruppert JM, Johnson MR, Frost AR: Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther; 2006 Jun;5(6):674-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer.
  • The hedgehog pathway regulates epithelial-mesenchymal interactions, differentiation, proliferation and survival during development.
  • Using real-time, quantitative PCR, laser capture microdissection, and immunohistochemistry, distinctive patterns of expression of the hedgehog pathway members patched 1 (PTCH1), smoothened, GLI1, GLI2 and the 3 hedgehog ligands were identified for epithelial cells and stromal fibroblasts in benign breast and breast cancer.
  • Hedgehog ligands were expressed at higher levels in some cancer epithelial cell lines compared to noncancerous epithelial cells.
  • Correspondingly, expression of GLI1, a transcription factor and transcriptional product of hedgehog signaling, was increased 8-fold in cancer epithelial cell lines; however, PTCH1, also a transcriptional target of hedgehog signaling in many cell types, was not increased.
  • Hedgehog-mediated transcription, as indicated by a reporter of GLI-dependent promoter activity and by expression of GLI1 transcripts, was reduced by the hedgehog pathway inhibitor cyclopamine in both MDA-MB-435 cancer epithelial cells and MCF10AT epithelial cells, a cell line derived from benign breast.
  • However, cyclopamine reduced viability of cancer epithelial cell lines, including MDA-MB-435, but did not specifically affect fibroblasts or epithelial cells from benign breast, including MCF10AT.
  • These results demonstrate modulation of GLI-mediated transcription in both cancer and benign-derived epithelial cells by cyclopamine and sonic hedgehog, and further suggest that hedgehog signaling contributes to the survival of only the cancer epithelial cells.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 2002 Apr;17(2):623-37 [11962762.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6 [16488983.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):923-8 [12615704.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):508-13 [12652302.001]
  • [Cites] J Endocrinol. 2003 Sep;178(3):467-78 [12967338.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 6;314(2):313-20 [14733907.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] Biochem J. 2004 Mar 1;378(Pt 2):353-62 [14611647.001]
  • [Cites] J Agric Food Chem. 2004 May 19;52(10):2832-9 [15137822.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3479-85 [15150101.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2577-85 [15277480.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):165-81 [15300011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]
  • [Cites] Development. 2004 Oct;131(20):5009-19 [15371305.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Int J Mol Med. 2004 Nov;14(5):793-9 [15492847.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Science. 1997 May 2;276(5313):817-21 [9115210.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):711-3 [10505029.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:29 [15482598.001]
  • [Cites] Breast Cancer Res. 2005;7(1):R46-59 [15642169.001]
  • [Cites] Development. 1999 Nov;126(22):5181-93 [10529434.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):236-43 [10981877.001]
  • [Cites] Nature. 2001 Feb 1;409(6820):633-7 [11214324.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1320-6 [11245428.001]
  • [Cites] J Invest Dermatol. 2001 Mar;116(3):472-4 [11231326.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):97-104 [11322829.001]
  • [Cites] Dev Biol. 2001 Oct 1;238(1):133-44 [11783999.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):118-27 [11857395.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] Histol Histopathol. 2002 Apr;17(2):599-621 [11962761.001]
  • [Cites] Dev Biol. 2005 Apr 1;280(1):111-21 [15766752.001]
  • [Cites] Genomics. 2005 Apr;85(4):462-71 [15780749.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):306-17 [15803137.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Development. 2005 Jul;132(14):3267-79 [15983404.001]
  • [Cites] J Neurosci. 2005 Sep 7;25(36):8338-46 [16148242.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1698-705 [15905200.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):139-48 [16003737.001]
  • [Cites] Hum Mol Genet. 2005 Nov 15;14(22):3379-88 [16203740.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):107-15 [12241103.001]
  • (PMID = 16855373.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA091421; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / R01 CA087728; United States / NCI NIH HHS / CA / R03 CA105950
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Hedgehog Proteins; 0 / RNA, Neoplasm; 0 / SHH protein, human; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ NIHMS11622; NLM/ PMC1557635
  •  go-up   go-down


46. Agaimy A, Stoehr R, Vieth M, Hartmann A: Benign serrated colorectal fibroblastic polyps/intramucosal perineuriomas are true mixed epithelial-stromal polyps (hybrid hyperplastic polyp/mucosal perineurioma) with frequent BRAF mutations. Am J Surg Pathol; 2010 Nov;34(11):1663-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign serrated colorectal fibroblastic polyps/intramucosal perineuriomas are true mixed epithelial-stromal polyps (hybrid hyperplastic polyp/mucosal perineurioma) with frequent BRAF mutations.
  • Colorectal fibroblastic polyp and intramucosal perineurioma are 2 synonyms for a recently described benign mucosal lesion with a predilection for the rectosigmoid colon.
  • We analyzed the clinicopathological features of 29 fibroblastic polyps and investigated them for the first time for mutations known to be involved in serrated colorectal epithelial polyps (BRAF, KRAS, and PIK3CA).
  • Immunohistochemistry revealed expression of at least one perineurial cell marker (epithelial membrane antigen, claudin-1, and glucose transporter-1) in 26 out of 27 lesions (96%), but expression of CD34 was less common (8 of 27; 30%).
  • Our results indicate that serrated fibroblastic polyps/intramucosal perineuriomas represent a unique type of mixed epithelial-stromal polyps (hybrid hyperplastic polyp/mucosal perineurioma).
  • The perineurial stromal component might be derived from modified pericryptic fibroblasts as a consequence of a yet poorly understood epithelial-stromal interaction.
  • [MeSH-major] Adenoma / pathology. Colonic Polyps / pathology. Colorectal Neoplasms / pathology. Epithelial Cells / pathology. Fibroblasts / pathology. Intestinal Mucosa / pathology. Mutation. Nerve Sheath Neoplasms / pathology. Proto-Oncogene Proteins B-raf / genetics. Stromal Cells / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. DNA Mutational Analysis. Female. Humans. Hyperplasia. Immunohistochemistry. Male. Middle Aged. Phosphatidylinositol 3-Kinases / genetics. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20962618.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


47. Poczobutt JM, Tentler J, Lu X, Schedin PJ, Gutierrez-Hartmann A: Benign mammary epithelial cells enhance the transformed phenotype of human breast cancer cells. BMC Cancer; 2010;10:373
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign mammary epithelial cells enhance the transformed phenotype of human breast cancer cells.
  • However, the role of adjacent benign epithelial cells, which provide initial cell-cell contacts with cancer cells, in tumor progression has not been thoroughly examined.
  • In this report we addressed the question whether benign MECs alter the transformed phenotype of human breast cancer cells.
  • METHODS: We used both in vitro and in vivo co-cultivation approaches, whereby we mixed GFP-tagged MCF-10A cells (G2B-10A), as a model of benign mammary epithelial cells (MECs), and RFP-tagged MDA-MB-231-TIAS cells (R2-T1AS), as a model of breast cancer cells.
  • Moreover, two other models of benign MECs, MCF-12A and HuMECs, also enhanced R2-T1AS colony growth in soft agar and clonogenicity assays.
  • These data reveal that factors secreted by benign MECs are responsible for the observed enhancement of the R2-T1AS transformed phenotype.
  • Co-injecting R2-T1AS cells with G2B-10A cells +/- PFA-fixation, revealed that G2B-10A cells promoted a ~3-fold increase in tumor growth, irrespective of PFA pre-treatment.
  • CONCLUSIONS: Taken together, these data shift our understanding of adjacent benign epithelial cells in the cancer process, from passive, noncontributory cells to an active and tumor-promoting vicinal cell population that may have significant effects early, when benign cells outnumber malignant cells.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Epithelial Cells / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1995 Feb;95(2):859-73 [7532191.001]
  • [Cites] Science. 2002 Feb 1;295(5556):868-72 [11786607.001]
  • [Cites] J Cell Biol. 1997 Apr 7;137(1):231-45 [9105051.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):1063-8 [9615766.001]
  • [Cites] Breast Cancer Res Treat. 2002 Feb;71(3):269-80 [12002345.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] Breast Cancer Res Treat. 2003 Jun;79(3):287-99 [12846413.001]
  • [Cites] Science. 2004 Feb 6;303(5659):848-51 [14764882.001]
  • [Cites] Oncogene. 2004 Mar 4;23(9):1766-79 [14767472.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Sep;72(9):3585-9 [1059147.001]
  • [Cites] Nature. 1984 Jun 7-13;309(5968):552-6 [6203040.001]
  • [Cites] J Histochem Cytochem. 1985 Aug;33(8):845-53 [3894502.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):839-49 [15516957.001]
  • [Cites] Cell Death Differ. 2005 Feb;12(2):107-14 [15647754.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R274-83 [15987422.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2502-12 [16199153.001]
  • [Cites] Am J Pathol. 2006 Feb;168(2):608-20 [16436674.001]
  • [Cites] Cell Biol Int. 2006 Mar;30(3):227-38 [16427788.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):281-91 [16557280.001]
  • [Cites] Cancer Detect Prev. 2006;30(3):239-47 [16872754.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3871-6 [17360445.001]
  • [Cites] Breast Cancer Res Treat. 2007 Apr;102(2):129-35 [16927176.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1175-83 [17476347.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] J Clin Invest. 2007 Dec;117(12):3988-4002 [18060036.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4329-34 [18334633.001]
  • [Cites] Biol Reprod. 2008 Apr;78(4):586-94 [18057312.001]
  • [Cites] J Pathol. 2008 Apr;214(5):545-54 [18189329.001]
  • [Cites] Cancer Cell. 2008 May;13(5):394-406 [18455123.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14891-6 [18809919.001]
  • [Cites] Histochem Cell Biol. 2008 Dec;130(6):1079-90 [18953558.001]
  • [Cites] Cell Cycle. 2009 Apr 15;8(8):1127-32 [19282662.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2009 Jun;14(2):145-57 [19350209.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2009 Jun;14(2):87-98 [19381788.001]
  • [Cites] Cell Prolif. 1999 Dec;32(6):351-61 [10646687.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1254-60 [10728684.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12072-7 [11593017.001]
  • [Cites] Int J Cancer. 1997 Mar 28;71(1):42-8 [9096664.001]
  • (PMID = 20637104.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / Cytokines
  • [Other-IDs] NLM/ PMC2913961
  •  go-up   go-down


48. Ouellet V, Ling TH, Normandin K, Madore J, Lussier C, Barrès V, Bachvarov D, Rancourt C, Tonin PN, Provencher DM, Mes-Masson AM: Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors. BMC Cancer; 2008;8:346
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors.
  • BACKGROUND: Serous epithelial ovarian tumors can be subdivided into benign (BOV), low malignant potential (LMP) or borderline and invasive (TOV) tumors.
  • Although the molecular characteristics of serous BOV, LMP and low grade (LG) TOV tumors has been initiated, definitive immunohistochemical markers to distinguish between these tumor types have not been defined.
  • METHODS: In the present study, we used a tissue array composed of 27 BOVs, 78 LMPs and 23 LG TOVs to evaluate the protein expression of a subset of selected candidates identified in our previous studies (Ape1, Set, Ran, Ccne1 and Trail) or known to be implicated in epithelial ovarian cancer disease (p21, Ccnb1, Ckd1).
  • RESULTS: Statistically significant difference in protein expression was observed for Ccnb1 when BOV tumors were compared to LMP tumors (p = 0.003).
  • When BOV were compared to LG TOV tumors, Trail was significantly expressed at a higher level in malignant tumors (p = 0.01).
  • Expression of p21 was significantly lower in LG tumors when compared with either BOVs (p = 0.03) or LMPs (p = 0.001).
  • We also observed that expression of p21 was higher in LMP tumors with no (p = 0.02) or non-invasive (p = 0.01) implants compared to the LMP associated with invasive implants.
  • CONCLUSION: This study represents an extensive analyse of the benign and highly differentiated ovarian disease from an immunohistochemical perspective.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):175-81 [18317226.001]
  • [Cites] Virchows Arch. 2000 Mar;436(3):224-8 [10782880.001]
  • [Cites] Pathol Biol (Paris). 2000 Apr;48(3):190-202 [10858953.001]
  • [Cites] Hum Pathol. 2000 Jun;31(6):698-704 [10872663.001]
  • [Cites] Virchows Arch. 2000 May;436(5):403-12 [10881733.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3131-8 [10955794.001]
  • [Cites] Hum Pathol. 2000 Dec;31(12):1506-14 [11150376.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1B):521-8 [11299798.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] Oncogene. 2002 Aug 22;21(37):5804-13 [12173052.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1111-28 [12218568.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3865-71 [12228206.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2002 Aug;16(4):499-512 [12413931.001]
  • [Cites] Cancer. 2003 May 15;97(10 Suppl):2631-42 [12733128.001]
  • [Cites] Histol Histopathol. 2003 Jul;18(3):761-70 [12792888.001]
  • [Cites] J Pathol. 2003 Jul;200(3):327-35 [12845629.001]
  • [Cites] Ann Oncol. 2003 Jul;14(7):1078-85 [12853350.001]
  • [Cites] Virchows Arch. 2003 Jul;443(1):38-43 [12756564.001]
  • [Cites] Gut. 2004 Feb;53(2):235-40 [14724156.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Oct;83 Suppl 1:135-66 [14763172.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Mar;149(2):98-106 [15036884.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9309-14 [15184677.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):918-33 [15297960.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):934-48 [15297961.001]
  • [Cites] Bull Cancer. 1982;69(3):228-38 [6289947.001]
  • [Cites] Mod Pathol. 1988 Nov;1(6):407-14 [2464824.001]
  • [Cites] Hum Pathol. 1990 Apr;21(4):397-403 [2318481.001]
  • [Cites] Hematol Oncol Clin North Am. 1992 Aug;6(4):739-60 [1500384.001]
  • [Cites] Hematol Oncol Clin North Am. 1992 Aug;6(4):761-82 [1500385.001]
  • [Cites] Int J Gynecol Pathol. 1993 Jan;12(1):20-7 [7678103.001]
  • [Cites] Cell. 1993 Nov 19;75(4):805-16 [8242751.001]
  • [Cites] Cell. 1993 Nov 19;75(4):817-25 [8242752.001]
  • [Cites] Nature. 1993 Dec 16;366(6456):701-4 [8259214.001]
  • [Cites] Hum Pathol. 1996 Jun;27(6):521-7 [8666359.001]
  • [Cites] Cancer. 1996 Jul 15;78(2):278-86 [8674004.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1319-30 [8898836.001]
  • [Cites] Biochem Biophys Res Commun. 1997 May 19;234(2):300-2 [9177263.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):397-409 [10199469.001]
  • [Cites] Mol Cancer. 2004 Oct 7;3:27 [15471544.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):218-24 [15644779.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1053-65 [15558012.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S33-50 [15761465.001]
  • [Cites] Int J Gynecol Cancer. 2005 May-Jun;15(3):453-61 [15882169.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):707-23 [15897738.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4672-87 [15940270.001]
  • [Cites] Oncol Rep. 2005 Aug;14(2):363-8 [16012716.001]
  • [Cites] Histopathology. 2005 Sep;47(3):310-5 [16115232.001]
  • [Cites] Oncol Rep. 2005 Oct;14(4):837-46 [16142340.001]
  • [Cites] Semin Oncol. 2005 Oct;32(5):452-7 [16210085.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7273-9 [16243797.001]
  • [Cites] Histol Histopathol. 2006 Jan;21(1):81-92 [16267789.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10602-12 [16288054.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):599-607 [16572426.001]
  • [Cites] Clin Obstet Gynecol. 2006 Sep;49(3):517-25 [16885658.001]
  • [Cites] Int J Cancer. 2006 Nov 1;119(9):2119-26 [16823850.001]
  • [Cites] J Pathol. 2006 Oct;210(2):147-54 [16850502.001]
  • [Cites] J Cell Physiol. 2007 Jan;210(1):183-91 [16998811.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jan;19(1):7-15 [10638449.001]
  • [Cites] Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9 [17218844.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2007 Feb;13(1):9-14 [17392664.001]
  • [Cites] Exp Oncol. 2007 Mar;29(1):49-53 [17431389.001]
  • [Cites] Clin Med Res. 2007 Mar;5(1):35-44 [17456833.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):297-308 [17569106.001]
  • (PMID = 19032793.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2610034
  •  go-up   go-down


49. Gursan N, Sipal S, Calik M, Gundogdu C: P53, bcl-2, ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms. Eurasian J Med; 2009 Apr;41(1):10-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P53, bcl-2, ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms.
  • OBJECTIVE: Approximately 50% of human malignancies present with mutations in p53, which is the most common tumor suppressor gene involved with human malignancies.
  • The purpose of this study was to determine whether simultaneous detection of p53, bcl-2 and Ki-67 using immunohistochemical staining can be used as a diagnostic factor in the assessment of human ovarian epithelial tumors.
  • MATERIALS AND METHODS: The study was performed on formalin-fixed, paraffin-embedded tissue samples from 75 epithelial ovarian tumors, 15 serous cystadenomas, 15 mucinous cystadenomas, 5 borderline serous cystadenomas, 5 borderline mucinous cystadenomas, 15 serous cystadenocarcinomas, 15 mucinous cystadenocarcinomas and 5 endometrioid carcinomas.
  • RESULTS: Anti-p53 reactivity was observed in 14 tumors, all of which were malignant tumors, and no reactivity was observed in borderline or benign tumors.
  • Overexpression of bcl-2 was observed in 12 benign neoplasms (40%), 5 of which were borderline (50%), but was not observed in any of the malignant tumors.
  • There was a statistically significantly higher level of Ki-67 LI positivity in the malignant tumors than in the benign and borderline tumors (p<0.005).
  • CONCLUSION: These data show significant differences in the expression of these markers in ovarian tumors and suggest a possible role for these tumor-associated genes as supplemental tools in diagnostic pathology.
  • Furthermore, our findings support the redesignation of low malignant potential tumors (current nomenclature) to benign ovarian carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25610057.001).
  • [ISSN] 1308-8734
  • [Journal-full-title] The Eurasian journal of medicine
  • [ISO-abbreviation] Eurasian J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC4261648
  • [Keywords] NOTNLM ; Ki-67 / Ovarian cancer / bcl-2 / p53
  •  go-up   go-down


50. Haruki T, Nakamura H, Taniguchi Y, Miwa K, Adachi Y, Fujioka S: Pulmonary mucinous cystadenoma: a rare benign tumor of the lung. Gen Thorac Cardiovasc Surg; 2010 Jun;58(6):287-90
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary mucinous cystadenoma: a rare benign tumor of the lung.
  • This tumor is histologically characterized by a benign proliferation of mucin-producing epithelial cells and bulky mucin inside the tumor.
  • We present the case of a 71-year-old woman with increasing mass shadow on chest radiography who underwent tumor resection by video-assisted thoracic surgery.
  • The tumor was diagnosed histologically as PMCA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20549459.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


51. Mandal S, Varma K, Khurana N, Mandal AK: Calcifying epithelial odontogenic tumor: report of two cases. Indian J Pathol Microbiol; 2008 Jul-Sep;51(3):397-8
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcifying epithelial odontogenic tumor: report of two cases.
  • Calcifying epithelial odontogenic tumor (CEOT) is a rare, benign odontogenic tumor.
  • It constitutes 0.4-3% of all odontogenic tumors.
  • Microscopically, these are composed of large sheets of epithelial cells, amorphous amyloid-like material and calcification.
  • Although these lesions are benign, they can be locally aggressive, but malignant transformation and metastasis is rare.
  • [MeSH-major] Calcinosis. Mouth Neoplasms / diagnosis. Mouth Neoplasms / pathology. Odontogenic Tumors / diagnosis. Odontogenic Tumors / pathology. Palate, Hard / pathology

  • Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18723969.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


52. Chung EM, Cube R, Lewis RB, Conran RM: From the archives of the AFIP: Pediatric liver masses: radiologic-pathologic correlation part 1. Benign tumors. Radiographics; 2010 May;30(3):801-26
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From the archives of the AFIP: Pediatric liver masses: radiologic-pathologic correlation part 1. Benign tumors.
  • Benign hepatic tumors in children include lesions that are unique to the pediatric age group and others that are more common in adults.
  • Infantile hemangioendothelioma, or infantile hepatic hemangioma, is a benign vascular tumor that may cause serious clinical complications.
  • The mesenchymal component or cystic component may predominate; this predominance determines the imaging appearance of the tumor.
  • Benign epithelial tumors that are common in adults may infrequently occur in childhood.
  • Knowledge of how the pathologic features of these tumors affect their imaging appearances helps radiologists offer an appropriate differential diagnosis and management plan.

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20462995.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Räsänen K, Vaheri A: TGF-beta1 causes epithelial-mesenchymal transition in HaCaT derivatives, but induces expression of COX-2 and migration only in benign, not in malignant keratinocytes. J Dermatol Sci; 2010 May;58(2):97-104
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TGF-beta1 causes epithelial-mesenchymal transition in HaCaT derivatives, but induces expression of COX-2 and migration only in benign, not in malignant keratinocytes.
  • BACKGROUND: Transforming growth factor beta (TGF-beta) acts as a tumor promoter by inducing epithelial-mesenchymal transition (EMT), which leads to a motile phenotype, enabling invasion and metastasis of cancer cells.
  • Cancer-related inflammation, mediated by prostaglandins, has been proposed as a critical mechanism in conversion of benign cells to malignant.
  • OBJECTIVE: Induction of cyclooxygenase 2 (COX-2), producer of prostaglandins, is thought to be a prerequisite for TGF-beta-induced EMT in benign cells.
  • RESULTS: TGF-beta1 caused proliferation arrest of benign and malignant HaCaT cells, and changed the epithelial morphology of benign and low-grade malignant cells, but not metastatic cells, to mesenchymal spindle-shape.
  • Epithelial junction proteins ZO-1 and E-cadherin were downregulated in all cell lines in response to TGF-beta1, but mesenchymal markers were not induced, suggesting a partial EMT response.
  • COX-2 and migration were induced only in benign HaCaT derivatives.
  • Malignant derivatives did not induce COX-2 in response to TGF-beta 1 treatment, thus emphasizing the role of inflammation in EMT response of benign cells.
  • CONCLUSIONS: TGF-beta1 operates via distinct mechanisms in inducing EMT and metastasis, and supporting this we show that TGF-beta1 induces COX-2 and promotes the migration of benign cells, but does not further augment the migration of malignant cells, indicating their resistance to TGF-beta1 in the context of motility.
  • [MeSH-major] Epithelium / metabolism. Gene Expression Regulation, Neoplastic. Keratinocytes / metabolism. Mesoderm / metabolism. Transforming Growth Factor beta1 / physiology
  • [MeSH-minor] Cell Line, Tumor. Cell Movement. Cell Proliferation. Chemotaxis. Humans. Immunohistochemistry / methods. Models, Biological. Neoplasm Metastasis. Transforming Growth Factor beta / metabolism. Wound Healing

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20399617.001).
  • [ISSN] 1873-569X
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


54. Mandinova A, Kolev V, Neel V, Hu B, Stonely W, Lieb J, Wu X, Colli C, Han R, Pazin MJ, Ostano P, Dummer R, Brissette JL, Dotto GP: A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans. J Clin Invest; 2009 Oct;119(10):3127-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans.
  • Seborrheic keratoses (SKs) are common, benign epithelial tumors of the skin that do not, or very rarely, progress into malignancy, for reasons that are not understood.
  • We investigated this by gene expression profiling of human SKs and cutaneous squamous cell carcinomas (SCCs) and found that several genes previously connected with keratinocyte tumor development were similarly modulated in SKs and SCCs, whereas the expression of others differed by only a few fold.
  • Knockdown of FOXN1 expression in primary human keratinocytes cooperated with oncogenic RAS in the induction of SCC-like tumors, whereas increased FOXN1 expression triggered the SCC cells to shift to a benign SK-like tumor phenotype, which included increased FGFR3 expression.
  • Thus,we have uncovered a positive regulatory loop between FGFR3 and FOXN1 that underlies a benign versus malignant skin tumor phenotype.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2006 Apr 15;20(8):1028-42 [16618808.001]
  • [Cites] J Clin Invest. 2006 Aug;116(8):2201-2207 [16841094.001]
  • [Cites] J Invest Dermatol. 2006 Nov;126(11):2404-7 [16778799.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3465-71 [16849642.001]
  • [Cites] Oral Oncol. 2007 Jan;43(1):60-6 [16807070.001]
  • [Cites] EMBO J. 2007 Mar 7;26(5):1268-78 [17304214.001]
  • [Cites] Genes Dev. 2007 Mar 1;21(5):562-77 [17344417.001]
  • [Cites] Mol Cell Biol. 2007 May;27(10):3732-42 [17353266.001]
  • [Cites] J Invest Dermatol. 2007 Aug;127(8):1883-5 [17392824.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13450-4 [17673550.001]
  • [Cites] Cell. 2007 Sep 7;130(5):932-42 [17803914.001]
  • [Cites] Differentiation. 2007 Oct;75(8):694-701 [17459087.001]
  • [Cites] World J Urol. 2007 Dec;25(6):581-93 [17912529.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):342-6 [18223206.001]
  • [Cites] Neoplasia. 2008 Jan;10(1):1-7 [18231634.001]
  • [Cites] Curr Urol Rep. 2008 Jan;9(1):55-61 [18366975.001]
  • [Cites] EMBO J. 2008 Apr 23;27(8):1243-54 [18388864.001]
  • [Cites] Nat Cell Biol. 2008 Aug;10(8):902-11 [18604200.001]
  • [Cites] Curr Opin Oncol. 2006 May;18(3):228-33 [16552233.001]
  • [Cites] Adv Dermatol. 1999;14:307-57 [10643503.001]
  • [Cites] J Bone Miner Res. 2000 Jan;15(1):155-65 [10646125.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):690-8 [10793105.001]
  • [Cites] N Engl J Med. 2001 Mar 29;344(13):975-83 [11274625.001]
  • [Cites] J Invest Dermatol. 2001 Apr;116(4):506-10 [11286615.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2453-64 [11402340.001]
  • [Cites] J Korean Med Sci. 2001 Oct;16(5):619-22 [11641533.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • [Cites] J Invest Dermatol. 2002 Feb;118(2):303-9 [11841548.001]
  • [Cites] Cell Signal. 2002 Jul;14(7):585-93 [11955951.001]
  • [Cites] Curr Opin Hematol. 2002 Jul;9(4):288-93 [12042702.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1105-14 [12357246.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):444-51 [12778134.001]
  • [Cites] Dev Cell. 2003 Jun;4(6):865-77 [12791271.001]
  • [Cites] Blood. 2003 Jul 15;102(2):772-3 [12835230.001]
  • [Cites] CA Cancer J Clin. 2003 Sep-Oct;53(5):292-302 [14570228.001]
  • [Cites] Nat Immunol. 2003 Nov;4(11):1128-35 [14528302.001]
  • [Cites] Am Fam Physician. 2003 Nov 15;68(10):1963-8 [14655805.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4555-62 [15231666.001]
  • [Cites] J Cell Sci. 2004 Aug 15;117(Pt 18):4157-68 [15316080.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6035-40 [15342384.001]
  • [Cites] Cancer Res. 1981 May;41(5):1657-63 [7214336.001]
  • [Cites] Cancer Res. 1985 Mar;45(3):1187-97 [2578876.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4477-80 [8402617.001]
  • [Cites] Mol Carcinog. 1994 Sep;11(1):19-28 [7916986.001]
  • [Cites] Nature. 1994 Nov 3;372(6501):103-7 [7969402.001]
  • [Cites] Genomics. 1995 Aug 10;28(3):549-59 [7490093.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):15292-7 [8663044.001]
  • [Cites] Genes Dev. 1996 Sep 1;10(17):2212-21 [8804315.001]
  • [Cites] Science. 1997 Jan 17;275(5298):400-2 [8994040.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3842-7 [9108066.001]
  • [Cites] Immunogenetics. 1997;46(6):509-15 [9321431.001]
  • [Cites] Trends Biochem Sci. 1998 Feb;23(2):59-62 [9538690.001]
  • [Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):136-42 [9627707.001]
  • [Cites] Med Clin North Am. 1998 Nov;82(6):1285-307, v-vi [9889749.001]
  • [Cites] Genes Dev. 1999 Mar 1;13(5):607-19 [10072388.001]
  • [Cites] Dev Biol. 1999 Apr 15;208(2):362-74 [10191051.001]
  • [Cites] Nature. 1999 Apr 8;398(6727):473-4 [10206641.001]
  • [Cites] Hum Mol Genet. 2005 May 1;14(9):1153-60 [15772091.001]
  • [Cites] J Invest Dermatol. 2005 May;124(5):867-76 [15854024.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):107-37 [15863029.001]
  • [Cites] Dev Cell. 2005 May;8(5):665-76 [15866158.001]
  • [ErratumIn] J Clin Invest. 2010 Feb;120(2):6455. Pazin, Mike [corrected to Pazin, Michael J]
  • (PMID = 19729838.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR39190; United States / NCI NIH HHS / CA / CA16038; United States / NIAMS NIH HHS / AR / R01 AR045284; United States / NIAMS NIH HHS / AR / AR054856; United States / NCI NIH HHS / CA / R01 CA073796; United States / Intramural NIH HHS / / ZIA AG000378-03; United States / NIAMS NIH HHS / AR / AR045284-11A1; United States / NIAMS NIH HHS / AR / R01 AR045284-11A1; United States / NIAMS NIH HHS / AR / R01 AR039190; United States / NIAMS NIH HHS / AR / R01 AR055218-02; United States / NCI NIH HHS / CA / P01 CA016038; United States / NCI NIH HHS / CA / CA73796; United States / NIAMS NIH HHS / AR / AR055218-02; United States / NIAMS NIH HHS / AR / AR045284; United States / NIAMS NIH HHS / AR / R01 AR055218; United States / NIAMS NIH HHS / AR / R01 AR054856
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Forkhead Transcription Factors; 0 / Whn protein; EC 2.7.10.1 / FGFR3 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3
  •  go-up   go-down


55. Kilic N, Tilki D, Ergün B, Seitz M, Stief CG, Reich O, Ergün S: Epithelial versus endothelial CEACAM1 expression and angiogenesis in epididymal adenomatoid tumor. Anticancer Res; 2010 Jul;30(7):2651-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial versus endothelial CEACAM1 expression and angiogenesis in epididymal adenomatoid tumor.
  • BACKGROUND/AIM: To study the expression of the pro-angiogenic factor carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1) in epididymal adeno-matoid tumor tissue, a very rare benign neoplasia, in relation to its vascularization.
  • MATERIALS AND METHODS: Immunohistochemistry for CEACAM1 and for both endothelial markers CD31 and CD34 was performed in normal human epididymal and epididymal adenomatoid tumor tissue.
  • The vessel density was calculated in four tumor regions with different degrees of vascularization in comparison to the vascularization of the normal epididymal tissue.
  • RESULTS: CEACAM1 was found in normal epididymal epithelium, while the epithelium of tumor glands was mostly negative.
  • Only few blood vessels and lymphatics in adenomatoid tumor tissue expressed CEACAM1.
  • The assessment of vascularization revealed either equal or a significantly lower vessel density in some adenomatoid tumor regions in comparison to normal epididymal tissue.
  • DISCUSSION: These data demonstrate that despite its epithelial down-regulation, CEACAM1 is not present in the majority of adenomatoid tumor blood vessels, which might be related to the lower angiogenic activity and benign behaviour of this tumor.
  • [MeSH-major] Adenomatoid Tumor / blood supply. Antigens, CD / biosynthesis. Cell Adhesion Molecules / biosynthesis. Testicular Neoplasms / blood supply
  • [MeSH-minor] Antigens, CD31 / biosynthesis. Antigens, CD34 / biosynthesis. Endothelial Cells / metabolism. Epididymis / blood supply. Epididymis / metabolism. Epithelial Cells / metabolism. Humans. Immunohistochemistry. Male. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20682994.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / CD66 antigens; 0 / Cell Adhesion Molecules
  •  go-up   go-down


56. Amat Villegas I, Gómez Dorronsoro ML, López Caballero MC, del Llano Varela P, Pascual Piérola JI, Begoña Larrinaga M: [Metanephric stromal tumor: report of two cases and bibliographic review]. Arch Esp Urol; 2006 Jan-Feb;59(1):88-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metanephric stromal tumor: report of two cases and bibliographic review].
  • [Transliterated title] Tumor del estroma metanéfrico: presentación de dos casos en adultos y revisión de la literatura.
  • OBJECTIVE: Metanephric Stromal Tumors (MST) are pediatric renal neoplasms not very common in adults.
  • This study revises its classification, incidence and evolution and also some specific characteristics of the cases diagnosed in adults.
  • The tumors were completely resected.
  • According to the 2002 ONS classification of tumours of the urinary system, they have been revised and re-classified as MST CONCLUSION: MST are pediatric benign tumors exceptionally diagnosed in adults.
  • Metanephric stromal tumors are divided into 3 categories based on the presence of epithelial cells, stroma and epithelial cells plus stromal.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16568701.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 7
  •  go-up   go-down


57. Moslemi MK: Mixed epithelial and stromal tumor of the kidney or adult mesoblastic nephroma: an update. Urol J; 2010;7(3):141-7
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for mesoblastic nephroma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed epithelial and stromal tumor of the kidney or adult mesoblastic nephroma: an update.
  • PURPOSE: Our aim was to review the spectrum of usual and unusual clinical and morphologic findings observed in mixed epithelial and stromal tumor of the kidney (MEST).
  • RESULTS: Mixed epithelial and stromal tumor is a relatively rare and distinct neoplasm of the kidney that should be distinguished from other renal neoplasms.
  • Although the overall prognosis is favorable, recurrence and malignant transformation of MEST can occur CONCLUSION: It is difficult to distinguish benign or malignant nature on imaging studies.


58. Seili-Bekafigo I, Jonjić N, Stemberger C, Rajković-Molek K: Additional cytomorphological criteria in diagnosis of pilomatricoma--benign tumor with bad reputation. Coll Antropol; 2010 Mar;34(1):117-22
Hazardous Substances Data Bank. METHYLENE BLUE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additional cytomorphological criteria in diagnosis of pilomatricoma--benign tumor with bad reputation.
  • Pilomatricomas (PM) are benign skin appendageal tumors, with differentiation towards hair-forming cells, usually found in children.
  • PM are often mistaken for "small round blue cell" tumors in children, or for Merkel cell carcinoma, basalioma and metastatic small cell carcinoma in adults, with possible over-aggressive therapeutic approach.
  • Clinical, cytomorphologic and basic morphometric features were analyzed, and compared with 4 cases of malignant tumors with similar clinical presentation.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Carcinoma, Basal Cell / pathology. Carcinoma, Merkel Cell / pathology. Child. Diagnosis, Differential. Eosine Yellowish-(YS). Epithelial Cells / pathology. Female. Humans. Male. Methylene Blue. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432739.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / May-Grunwald Giemsa; T42P99266K / Methylene Blue; TDQ283MPCW / Eosine Yellowish-(YS)
  •  go-up   go-down


59. Duchi S, Fagnocchi L, Cavaliere V, Hsouna A, Gargiulo G, Hsu T: Drosophila VHL tumor-suppressor gene regulates epithelial morphogenesis by promoting microtubule and aPKC stability. Development; 2010 May;137(9):1493-503
FlyBase. FlyBase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drosophila VHL tumor-suppressor gene regulates epithelial morphogenesis by promoting microtubule and aPKC stability.
  • Mutations in the human von Hippel-Lindau (VHL) genes are the cause of VHL disease, which displays multiple benign and malignant tumors.
  • Using an established follicular epithelial model in Drosophila, we show that the Drosophila VHL gene is involved in epithelial morphogenesis via stabilizing microtubule bundles and aPKC.
  • Microtubule defects in VHL mutants lead to mislocalization of aPKC and subsequent loss of epithelial integrity.
  • Destabilizing microtubules in ex vivo culture of wild-type egg chambers can also result in aPKC mislocalization and epithelial defects.
  • The results establish a developmental function of the VHL gene that is relevant to its tumor-suppressor activity.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 1993 Apr;117(4):1223-37 [8404527.001]
  • [Cites] Development. 2008 Feb;135(3):463-71 [18094021.001]
  • [Cites] Dev Biol. 1994 Oct;165(2):352-60 [7958405.001]
  • [Cites] Cell. 1995 Jul 14;82(1):67-76 [7606787.001]
  • [Cites] Development. 1997 Oct;124(19):3871-80 [9367443.001]
  • [Cites] Mol Cell. 1998 Jun;1(7):959-68 [9651579.001]
  • [Cites] Exp Cell Res. 2004 Dec 10;301(2):139-46 [15530850.001]
  • [Cites] Oncogene. 2004 Nov 11;23(53):8688-94 [15467749.001]
  • [Cites] Curr Biol. 2005 Feb 8;15(3):276-82 [15694314.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Mar;6(3):233-47 [15738988.001]
  • [Cites] Biochem J. 2006 Jan 15;393(Pt 2):471-80 [16176182.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1553-60 [16452212.001]
  • [Cites] J Cell Sci. 2006 Mar 15;119(Pt 6):979-87 [16525119.001]
  • [Cites] J Biol Chem. 2006 Apr 28;281(17):12069-80 [16505488.001]
  • [Cites] J Am Soc Nephrol. 2006 Jul;17(7):1801-6 [16775032.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6903-7 [16849532.001]
  • [Cites] Cell Cycle. 2006 Sep;5(18):2054-6 [16969113.001]
  • [Cites] J Cell Sci. 2006 Oct 15;119(Pt 20):4155-63 [17038542.001]
  • [Cites] J Cell Biol. 2006 Nov 20;175(4):547-54 [17101696.001]
  • [Cites] Dev Cell. 2007 May;12(5):727-38 [17488624.001]
  • [Cites] FEBS Lett. 2007 Oct 2;581(24):4571-6 [17825299.001]
  • [Cites] Mol Cell. 2007 Oct 12;28(1):15-27 [17936701.001]
  • [Cites] Nat Protoc. 2007;2(10):2467-73 [17947988.001]
  • [Cites] Curr Opin Cell Biol. 2007 Dec;19(6):685-90 [18006292.001]
  • [Cites] Nat Cell Biol. 2008 Mar;10(3):361-9 [18297059.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4649-57 [18559510.001]
  • [Cites] Nat Cell Biol. 2008 Oct;10(10):1208-16 [18806787.001]
  • [Cites] Nat Rev Cancer. 2008 Nov;8(11):865-73 [18923434.001]
  • [Cites] Mol Biol Cell. 2009 Feb;20(3):1089-101 [19073886.001]
  • [Cites] Dev Biol. 2009 May 15;329(2):294-305 [19285057.001]
  • [Cites] Nat Cell Biol. 2009 Aug;11(8):994-1001 [19620968.001]
  • [Cites] Nature. 1999 Dec 2;402(6761):544-7 [10591216.001]
  • [Cites] Oncogene. 2000 Jun 1;19(24):2803-11 [10851083.001]
  • [Cites] Science. 2000 Jun 16;288(5473):2013-8 [10856208.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Sep 16;276(1):355-61 [11006129.001]
  • [Cites] J Cell Biol. 2000 Nov 13;151(4):891-904 [11076972.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2929-36 [12019174.001]
  • [Cites] Genes Dev. 2002 Jun 15;16(12):1568-81 [12080094.001]
  • [Cites] Bioessays. 2002 Aug;24(8):690-5 [12210528.001]
  • [Cites] Science. 2002 Dec 6;298(5600):1955-9 [12471248.001]
  • [Cites] Nat Cell Biol. 2003 Jan;5(1):46-52 [12510193.001]
  • [Cites] Nat Cell Biol. 2003 Jan;5(1):53-8 [12510194.001]
  • [Cites] Nat Cell Biol. 2003 Jan;5(1):64-70 [12510195.001]
  • [Cites] Nature. 2003 Apr 17;422(6933):766-74 [12700771.001]
  • [Cites] Curr Biol. 2003 Apr 29;13(9):734-43 [12725730.001]
  • [Cites] Traffic. 2004 Jan;5(1):1-9 [14675420.001]
  • [Cites] Dev Cell. 2004 Jun;6(6):845-54 [15177032.001]
  • [Cites] J Cell Biol. 2004 Aug 16;166(4):549-57 [15302858.001]
  • [Cites] Cell. 1990 Jun 1;61(5):787-99 [2344615.001]
  • [Cites] Eur J Hum Genet. 2008 Jan;16(1):73-8 [17912253.001]
  • [Cites] J Cell Sci. 1993 Aug;105 ( Pt 4):993-1000 [8227220.001]
  • (PMID = 20388653.001).
  • [ISSN] 1477-9129
  • [Journal-full-title] Development (Cambridge, England)
  • [ISO-abbreviation] Development
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA078582-100005; United States / NCI NIH HHS / CA / R01CA109860; United States / NCI NIH HHS / CA / R01 CA109860; United States / NCI NIH HHS / CA / P01 CA078582-100005; United States / NCI NIH HHS / CA / P01 CA078582; United States / NIGMS NIH HHS / GM / GM057843-08; United States / NIGMS NIH HHS / GM / R01 GM057843; United States / NIGMS NIH HHS / GM / R01 GM057843-08; United States / NCI NIH HHS / CA / R01 CA109860-06; United States / NCI NIH HHS / CA / P01CA78582; United States / NCI NIH HHS / CA / CA109860-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drosophila Proteins; EC 2.7.11.13 / Protein Kinase C-alpha; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  • [Other-IDs] NLM/ PMC2853850
  •  go-up   go-down


60. Behera MA, Dai Q, Garde R, Saner C, Jungheim E, Price TM: Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells. Am J Physiol Endocrinol Metab; 2009 Nov;297(5):E1089-96
Hazardous Substances Data Bank. CYCLOHEXIMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells.
  • The effects of progesterone on breast epithelial cells remain poorly defined with observations showing both proliferative and antiproliferative effects.
  • As an example, progesterone levels correlate with increased epithelial cell proliferation, but there is discordance between the dividing cells and the cells with nuclear progesterone receptor expression.
  • The release of paracrine growth factors from nuclear receptor-positive cells has been postulated as a mechanism, since in vitro studies show a lack of growth effect by progesterone in breast epithelial cells lacking nuclear receptors.
  • Our study demonstrates a nongenomic action of progesterone on benign breast epithelial cells, resulting in enhanced cellular respiration and protection from apoptosis.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Cell Cardiol. 1995 Oct;27(10):2167-76 [8576933.001]
  • [Cites] Genes Dev. 1995 Sep 15;9(18):2266-78 [7557380.001]
  • [Cites] Breast Cancer Res Treat. 1997 Sep;45(2):121-33 [9342437.001]
  • [Cites] Exp Cell Res. 1997 Oct 10;236(1):223-30 [9344602.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):4987-91 [9371488.001]
  • [Cites] J Biol Chem. 1999 Apr 30;274(18):12567-75 [10212235.001]
  • [Cites] Breast Cancer Res Treat. 1999 Feb;53(3):217-27 [10369068.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Nov;97(3):278-88 [16154741.001]
  • [Cites] Dev Cell. 2005 Dec;9(6):843-54 [16326395.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Feb;98(2-3):174-8 [16413775.001]
  • [Cites] J Biol Chem. 2006 Mar 3;281(9):5837-44 [16407197.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Mar;98(4-5):218-27 [16466914.001]
  • [Cites] Carcinogenesis. 2006 May;27(5):925-35 [16361271.001]
  • [Cites] Apoptosis. 2006 Apr;11(4):473-85 [16532373.001]
  • [Cites] Biochim Biophys Acta. 2006 May-Jun;1757(5-6):509-17 [16829228.001]
  • [Cites] Maturitas. 2006 Jul 20;54(4):327-34 [16806749.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2006 Nov;129(1):77-83 [16460873.001]
  • [Cites] Mol Endocrinol. 2006 Dec;20(12):3146-64 [16959873.001]
  • [Cites] FEBS J. 2007 Mar;274(6):1393-418 [17302740.001]
  • [Cites] Endocrinology. 2007 Jun;148(6):2723-36 [17332059.001]
  • [Cites] Cell Prolif. 2007 Oct;40(5):721-40 [17877612.001]
  • [Cites] Biol Chem. 2007 Oct;388(10):1113-9 [17937626.001]
  • [Cites] Mitochondrion. 2007 Dec;7(6):399-401 [17881297.001]
  • [Cites] Methods. 2008 Mar;44(3):222-8 [18314052.001]
  • [Cites] Breast. 2008 Apr;17(2):172-9 [17928227.001]
  • [Cites] Cell Res. 2009 Jan;19(1):140-8 [19079362.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Dec;84(12):4559-65 [10599719.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):867-72 [10706096.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):936-43 [10706108.001]
  • [Cites] Oncology. 2000;59 Suppl 1:39-44 [11096355.001]
  • [Cites] Mol Endocrinol. 2001 Feb;15(2):255-70 [11158332.001]
  • [Cites] Mol Cell Endocrinol. 2001 Jun 20;179(1-2):97-103 [11420134.001]
  • [Cites] Endocrinology. 2002 Aug;143(8):3071-82 [12130573.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):93-105 [12160089.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):420-30 [12189384.001]
  • [Cites] Breast Cancer Res. 2002;4(5):187-90 [12223122.001]
  • [Cites] Mol Endocrinol. 2003 Jan;17(1):117-27 [12511611.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2231-6 [12574519.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2237-42 [12601167.001]
  • [Cites] Mol Cell Endocrinol. 2003 Feb 28;200(1-2):155-63 [12644308.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):25-30 [12650698.001]
  • [Cites] Biochim Biophys Acta. 2004 Jul 23;1658(1-2):141-7 [15282185.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Aug;71(8):2942-5 [4528490.001]
  • [Cites] Nature. 1975 Feb 27;253(5494):746-7 [1113869.001]
  • [Cites] Cancer Res. 1978 Aug;38(8):2434-7 [667841.001]
  • [Cites] Exp Cell Res. 1988 Sep;178(1):143-53 [3409975.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Mol Endocrinol. 1990 Dec;4(12):1833-40 [2082185.001]
  • [Cites] Cancer Res. 1994 Jan 15;54(2):340-3 [8275464.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3868-77 [8033109.001]
  • [Cites] J Exp Med. 1994 Sep 1;180(3):917-23 [8064240.001]
  • [Cites] Am J Obstet Gynecol. 1997 Jan;176(1 Pt 1):123-8 [9024102.001]
  • (PMID = 19690070.001).
  • [ISSN] 1522-1555
  • [Journal-full-title] American journal of physiology. Endocrinology and metabolism
  • [ISO-abbreviation] Am. J. Physiol. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / 1R03HD-052770-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Inhibitor of Differentiation Protein 1; 0 / Protein Synthesis Inhibitors; 0 / Receptors, Progesterone; 0 / Transforming Growth Factor beta1; 4G7DS2Q64Y / Progesterone; 8L70Q75FXE / Adenosine Triphosphate; 98600C0908 / Cycloheximide; EC 3.4.21.- / Kallikreins; EC 3.4.22.- / Caspases; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


61. Hikino H, Nagaoka S, Miura H, Kurosumi M: Benign myoepithelioma of the breast: origin and development. Pathol Int; 2009 Jun;59(6):422-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign myoepithelioma of the breast: origin and development.
  • A case of benign myoepithelioma of the breast in a 55-year-old woman is described.
  • The tumor was a well-circumscribed solid mass, measuring 13 x 12 mm.
  • Histopathology indicated that the tumor was composed of entirely myoepithelial cells, which was confirmed by immunoreactivity to calponin and S-100.
  • There was no ductal differentiation in the tumor, and staining for pan-cytokeratin and epithelial membrane antigen was weak and negative, respectively.
  • Although the biological behavior of the tumor remains to be ascertained, the tumor was considered to be myoepithelioma with benign features due to mild nuclear pleomorphism, sparse mitotic figures, low Ki-67 labeling index and low S-phase fraction.
  • Diagnostic confusion between benign myoepithelioma and other myoepithelial-rich cell tumors is possible.
  • Considering the classification of myoepithelial tumor in the salivary glands, benign myoepithelioma of the breast may possess a different development process from adenomyoepithelioma.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Mastectomy. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19490475.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


62. Akbulut M, Zekioglu O, Terek MC, Ozdemir N: Lipoadenofibroma of the endometrium: a rare variant of benign mullerian mixed tumor. Arch Gynecol Obstet; 2008 Sep;278(3):283-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipoadenofibroma of the endometrium: a rare variant of benign mullerian mixed tumor.
  • OBJECTIVE: Adenofibroma is a form of mixed mesodermal tumor in which epithelial and stromal components are benign, and usually arises in the endometrium of postmenopausal women.
  • CONCLUSION: We suggest that uterine adenofibromas with lipomatous areas belong to the family of mixed tumor of Mullerian origin.
  • [MeSH-major] Adenofibroma / pathology. Endometrial Neoplasms / pathology. Mixed Tumor, Mullerian / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18236054.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


63. Deboni MC, Naclério-Homem Mda G, Pinto Junior DS, Traina AA, Cavalcanti MG: Clinical, radiological and histological features of calcifying epithelial odontogenic tumor: case report. Braz Dent J; 2006;17(2):171-4
Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, radiological and histological features of calcifying epithelial odontogenic tumor: case report.
  • The calcifying epithelial odontogenic tumor (CEOT) is a rare benign odontogenic neoplasm that accounts for approximately 1% of all odontogenic tumors.
  • A case of an advanced CEOT associated with an impacted right second molar in the mandible of a young black female patient is presented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16924348.001).
  • [ISSN] 0103-6440
  • [Journal-full-title] Brazilian dental journal
  • [ISO-abbreviation] Braz Dent J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  •  go-up   go-down


64. Capo-chichi CD, Yeasky TM, Heiber JF, Wang Y, Barber GN, Xu XX: Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models. Gynecol Oncol; 2010 Feb;116(2):269-75
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models.
  • OBJECTIVE: Current treatment options for epithelial ovarian cancer are limited and therapeutic development for recurrent and drug-resistant ovarian cancer is an urgent agenda.
  • Specifically, we examined the toxicity to hosts and specificity of targeting ovarian tumors using a Wv ovarian tumor model.
  • METHODS: We first tested recombinant VSV for oncolytic activity in a panel of human ovarian epithelial cancer, immortalized, and primary ovarian surface epithelial cells in culture.
  • Then, we tested VSV oncolytic therapy using the immune competent Wv mice that develop tubular adenomas, benign tumor lesions derived from ovarian surface epithelial cells.
  • RESULTS: The expression of GFP encoded by the recombinant VSV genome was detected in about 5% of primary ovarian surface epithelial cells (3 lines) up to 30 days without significantly altering the growth pattern of the cells, suggesting the lack of toxicity to the normal ovarian surface epithelial cells.
  • We found that regardless of the inoculation route (intra bursal, IP, or IV), VSV specifically infected and replicated in the in situ ovarian tumors in the Wv mice without significant activity in any other organs and tissues, and showed no detectable toxicity.
  • The epithelial tumor lesions were greatly reduced in VSV-targeted ovarian tumors in the Wv mice.
  • The efficient oncolytic activity of VSV for the "immortalized" non-tumorigenic ovarian surface epithelial cells suggests that the selective specificity extends from pre-neoplastic to overt cancer cells.
  • The results demonstrated the explicit targeting of ovarian epithelial tumors by VSV in immune competent, ovarian tumor-bearing mouse models, and further support the utility of VSV as an effective and safe anti-cancer agent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • [Cites] Nat Med. 2000 Jul;6(7):821-5 [10888934.001]
  • [Cites] J Virol. 2000 Oct;74(20):9580-5 [11000229.001]
  • [Cites] J Virol. 2001 Apr;75(7):3474-9 [11238874.001]
  • [Cites] J Virol. 2002 Jan;76(2):895-904 [11752178.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3605-11 [12839948.001]
  • [Cites] J Virol. 2003 Aug;77(16):8843-56 [12885903.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4967-77 [12941822.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):19-24 [14749123.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):51-65 [14749126.001]
  • [Cites] Trends Mol Med. 2004 May;10(5):210-6 [15121047.001]
  • [Cites] Hum Gene Ther. 2004 Sep;15(9):821-31 [15353037.001]
  • [Cites] J Natl Cancer Inst. 1972 May;48(5):1283-95 [4337905.001]
  • [Cites] J Cell Physiol. 1988 Mar;134(3):347-56 [2450877.001]
  • [Cites] Genes Dev. 1990 Mar;4(3):390-400 [1692559.001]
  • [Cites] EMBO J. 1990 Jun;9(6):1805-13 [1693331.001]
  • [Cites] Lab Invest. 1990 Jul;63(1):132-6 [2374399.001]
  • [Cites] J Virol. 2004 Dec;78(23):12747-61 [15542627.001]
  • [Cites] Viral Immunol. 2004;17(4):516-27 [15671748.001]
  • [Cites] Hepatology. 2005 Jan;41(1):196-203 [15619242.001]
  • [Cites] Cancer Gene Ther. 2005 Apr;12(4):350-8 [15565179.001]
  • [Cites] Mol Ther. 2007 Apr;15(4):651-9 [17299401.001]
  • [Cites] Am J Pathol. 2007 Apr;170(4):1325-36 [17392171.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1291-5 [18316546.001]
  • [Cites] J Mol Med (Berl). 2008 Apr;86(4):363-77 [18214411.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4506-10 [18559493.001]
  • [Cites] Semin Oncol. 2009 Apr;36(2):112-25 [19332246.001]
  • [Cites] Annu Rev Pathol. 2009;4:287-313 [18842102.001]
  • [Cites] Nat Rev Cancer. 2009 Jun;9(6):415-28 [19461667.001]
  • [Cites] Mol Cell Biol. 2009 Sep;29(17):4766-77 [19581290.001]
  • [Cites] Oncogene. 2005 Nov 21;24(52):7710-9 [16299531.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):965-76 [16294217.001]
  • [Cites] Oncogene. 2006 Jan 19;25(3):349-58 [16186807.001]
  • [Cites] Curr Opin Mol Ther. 2006 Aug;8(4):322-30 [16955695.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1546-57 [17077357.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2840-8 [17363607.001]
  • (PMID = 19932656.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083638-100010; United States / NCI NIH HHS / CA / R01 CA079716-11; United States / NCI NIH HHS / CA / CA095924-06; United States / NCI NIH HHS / CA / R01 CA099471-05; United States / NCI NIH HHS / CA / R01 CA095924-05; United States / NCI NIH HHS / CA / R01 CA79716; United States / NCI NIH HHS / CA / R01 CA099471; United States / NCI NIH HHS / CA / R01 CA75389; United States / NCI NIH HHS / CA / R01 CA079716; United States / NIAID NIH HHS / AI / R01 AI071193-01A2; United States / NIAID NIH HHS / AI / R01 AI071193; United States / NCI NIH HHS / CA / CA095924-05; United States / NCI NIH HHS / CA / CA083638-100010; United States / NCI NIH HHS / CA / CA128115-01A2; United States / NCI NIH HHS / CA / R01 CA095924-06; United States / NCI NIH HHS / CA / P01 CA128115-01A2; United States / NCI NIH HHS / CA / CA079716-11; United States / NIAID NIH HHS / AI / AI071193-01A2; United States / NCI NIH HHS / CA / P01 CA128115; United States / NCI NIH HHS / CA / P50 CA083638; United States / NIAID NIH HHS / AI / R01 AI079336; United States / NCI NIH HHS / CA / R01 CA095924; United States / NCI NIH HHS / CA / CA099471-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS161338; NLM/ PMC2813895
  •  go-up   go-down


65. Wang Q, Zhang P, Zhang Q, Wang X, Li J, Ma C, Sun W, Zhang L: Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J; 2008 Apr;49(2):192-200
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of CD137 and CD137L expression in human primary tumor tissues.
  • AIM: To assess the expression of CD137 and CD137L in human primary tumor tissues and their potential role in tumor immunity.
  • METHODS: Expression of CD137 and CD137L was assessed by immunohistochemistry in frozen sections of 12 human normal tissues, 15 benign tumors of epithelial or mesenchymal origin (adenoma and leiomyoma), and 36 malignant tumors of epithelial origin (squamous cell carcinoma and adenocarcinoma).
  • The expression of CD137L on 9 human tumor cell lines (3 hepatocarcinoma, 2 lung carcinoma, 2 colon carcinoma, 1 lymphoma, and 1 leukemia) was detected by reverse transcription polymerase chain reaction.
  • To analyze the role of CD137L expressed on tumor cells, we co-cultured tumor cells expressing CD137L with activated T lymphocytes expressing CD137 or with Chinese hamster ovary cells expressing CD137 and then detected by ELISA the levels of cytokines (IL-8, IFN-gamma) secreted by tumor cells or activated T cells.
  • RESULTS: The expression of CD137 and CD137L was observed only in human benign (2/15, 3/15) or malignant tumors (15/36, 21/36), but not in normal tissues (0/12, 0/12).
  • CD137 was expressed on the vessel walls within tumor tissues, whereas CD137L was expressed on tumor cells.
  • The expression of CD137 and CD137L was more common in malignant tumors, especially in moderate or low-differentiated tumors.
  • Furthermore, CD137L expression found on tumor cell lines was functional because the ligation of CD137L on lung squamous carcinoma cells L78 with CD137 on T cells induced IFN-gamma production by T cells, and ligation of CD137L on hepatocarcinoma cells HepG2.2.15 with CD137 triggered tumor cells to produce IL-8.
  • CONCLUSION: CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors.
  • [MeSH-minor] Cell Line, Tumor. Disease Progression. Humans. Immunohistochemistry. Signal Transduction. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Immunol Ther Exp (Warsz). 1999;47(5):275-9 [10604232.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2903-10 [10946324.001]
  • [Cites] Am J Clin Pathol. 2001 Apr;115(4):543-9 [11293902.001]
  • [Cites] J Immunol. 2001 Aug 1;167(3):1313-24 [11466348.001]
  • [Cites] J Immunol. 2002 May 15;168(10):4897-906 [11994439.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3459-65 [12067989.001]
  • [Cites] Eur J Immunol. 2002 Dec;32(12):3617-27 [12516549.001]
  • [Cites] Cell Immunol. 2003 Nov;226(1):37-44 [14746806.001]
  • [Cites] Transpl Int. 2004 Aug;17(7):351-61 [15349720.001]
  • [Cites] Blood. 1995 Feb 15;85(4):1043-52 [7849293.001]
  • [Cites] J Immunol. 1995 Oct 1;155(7):3360-7 [7561030.001]
  • [Cites] J Immunol. 1998 Mar 1;160(5):2488-94 [9498794.001]
  • [Cites] J Exp Med. 1998 Jun 1;187(11):1849-62 [9607925.001]
  • [Cites] Semin Immunol. 1998 Dec;10(6):481-9 [9826581.001]
  • [Cites] J Leukoc Biol. 2005 Mar;77(3):281-6 [15618293.001]
  • [Cites] Annu Rev Immunol. 2005;23:23-68 [15771565.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):122-33 [15831231.001]
  • [Cites] J Immunother. 2005 Sep-Oct;28(5):449-60 [16113601.001]
  • [Cites] Hum Gene Ther. 2006 Aug;17(8):798-806 [16942440.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2758-67 [17460060.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4910-8 [17878391.001]
  • (PMID = 18461674.001).
  • [ISSN] 1332-8166
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / 4-1BB Ligand; 0 / Antigens, CD137
  • [Other-IDs] NLM/ PMC2359873
  •  go-up   go-down


66. Gu Y, Kim KH, Ko D, Srivastava S, Moul JW, McLeod DG, Rhim JS: Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line. Anticancer Res; 2005 Jan-Feb;25(1A):1-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line.
  • However, the generation of long-term human prostate epithelial cell lines derived from primary human prostate epithelium have been unsuccessful due to the absence of in vitro immortalization.
  • We have successfully established an immortal human prostate epithelial cell line from primary benign tissues of African-American prostate cancer patients by using telomerase.
  • The actively proliferating secondary African-American prostate epithelial RC-165N cells, derived from benign prostate tissue of a radical prostatectomy specimen, were transduced through infection with a retrovirus vector expressing the human telomerase catalytic subunit (hTERT).
  • RC-165N/hTERT cells exhibit epithelial morphology.
  • These immortalized cells showed no cell growth in soft agar, and no tumor formation in SCID mice.
  • NKX 3.1 and epithelial cell specific cytokeratin 8, androgen receptor (AR), prostate stem cell antigen and p16, but not PSA.
  • [MeSH-minor] Cell Growth Processes / drug effects. Cell Growth Processes / physiology. DNA-Binding Proteins. Epithelial Cells / cytology. Epithelial Cells / drug effects. Epithelial Cells / enzymology. Epithelial Cells / physiology. Flutamide / pharmacology. Humans. Karyotyping. Male. Telomerase / genetics. Telomerase / metabolism. Transfection


67. Hagemann T, Binder C, Binder L, Pukrop T, Trümper L, Grimshaw MJ: Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. DNA Cell Biol; 2005 Nov;24(11):766-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells.
  • There is increased staining of endothelins (ET-1, -2, and -3) and receptors (ET-RA and -RB) in invasive breast tumors compared to nonneoplastic tissue, and ETs stimulate MCF-7 cell invasion in vitro.
  • We analyzed ETstimulation of benign and transformed mammary epithelial cells, and whether expression of ETs is sufficient to induce invasiveness.
  • In breast cancer patient serum, ET-1 was increased in those patients with lymph node metastases compared to those with no lymph node involvement; ETs, however, had no mitogenic effect on breast tumor cell lines in vitro.
  • The benign mammary epithelial cell line, hTERT-HME1, and the poorly invasive breast tumor cell line MCF-7 secreted low levels of ET-1, while the invasive cell lines SKBR3 and MDAMB231 secreted high levels.
  • In contrast to transformed cells, ET stimulation or overexpression did not induce an invasive phenotype in benign cells.
  • Benign cells do not respond to ETs, and ET expression is not sufficient to induce invasion; however, the level of ET production by tumor cells correlates with their invasiveness, and increasing expression of the ET axis promotes breast tumor cell invasion via both receptors, while MMP-14 is induced via ET-RA.
  • [MeSH-major] Breast Neoplasms / metabolism. Endothelins / biosynthesis. Epithelial Cells / metabolism. Receptor, Endothelin A / biosynthesis. Receptor, Endothelin B / biosynthesis
  • [MeSH-minor] Calcium / metabolism. Cell Line. Cell Line, Tumor. Endothelin-1 / blood. Endothelin-1 / metabolism. Enzyme Induction. Female. Humans. Lymphatic Metastasis. Mammary Glands, Human / metabolism. Mammary Glands, Human / pathology. Matrix Metalloproteinases / biosynthesis. Neoplasm Invasiveness. Phenotype. Signal Transduction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16274297.001).
  • [ISSN] 1044-5498
  • [Journal-full-title] DNA and cell biology
  • [ISO-abbreviation] DNA Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endothelin-1; 0 / Endothelins; 0 / Receptor, Endothelin A; 0 / Receptor, Endothelin B; EC 3.4.24.- / Matrix Metalloproteinases; SY7Q814VUP / Calcium
  •  go-up   go-down


68. Poomsawat S, Punyasingh J: Calcifying epithelial odontogenic tumor: an immunohistochemical case study. J Mol Histol; 2007 Mar;38(1):103-9
Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcifying epithelial odontogenic tumor: an immunohistochemical case study.
  • Calcifying epithelial odontogenic tumor (CEOT) is a rare benign odontogenic tumor.
  • Histologically, the case showed sheets of polyhedral epithelial cells with deep eosinophilic cytoplasm and prominent nuclei.
  • Globules of amyloid-like material among the tumor cells were prominent.
  • Tumor cells expressed laminins 1 and 5, fibronectin, cytokeratins and vimentin.
  • A number of dendritic cells among sheets of tumor cells were revealed with strong staining for S-100 protein and CD 1a.
  • [MeSH-major] Mandibular Neoplasms / metabolism. Mandibular Neoplasms / pathology. Neoplasm Proteins / metabolism. Odontogenic Cyst, Calcifying / metabolism. Odontogenic Cyst, Calcifying / pathology
  • [MeSH-minor] Adult. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cytoplasm / metabolism. Cytoplasm / pathology. Dendritic Cells / metabolism. Dendritic Cells / pathology. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318341.001).
  • [ISSN] 1567-2379
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


69. Turbiner J, Amin MB, Humphrey PA, Srigley JR, De Leval L, Radhakrishnan A, Oliva E: Cystic nephroma and mixed epithelial and stromal tumor of kidney: a detailed clinicopathologic analysis of 34 cases and proposal for renal epithelial and stromal tumor (REST) as a unifying term. Am J Surg Pathol; 2007 Apr;31(4):489-500
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic nephroma and mixed epithelial and stromal tumor of kidney: a detailed clinicopathologic analysis of 34 cases and proposal for renal epithelial and stromal tumor (REST) as a unifying term.
  • Cystic nephroma (CN) and mixed epithelial and stromal tumor (MEST) are rare benign renal neoplasms that have overlapping clinical and morphologic features, including predominance in middle-aged women, variably cystic architecture, eosinophilic cells, and hobnail cells lining the cysts and ovarian-type stroma.
  • The aim of this study was to analyze and compare the histologic features and immunohistochemical profile of these tumors.
  • Twenty tumors were diagnosed as CNs, 18 in women and 2 in men, their age ranged from 24 to 63 (mean 48; median 50) years.
  • Fourteen tumors were diagnosed as MESTs, all in women, their age ranged from 26 to 84 (mean 52; median 51) years.
  • Histologically, all tumors were well-circumscribed except for one MEST.
  • The stromal/epithelial ratio was approximately 2.3 in MESTs versus 0.3 in CNs; cellular ovarian-type stroma composed 45% of the stroma in MESTs and 12% of the stroma of CNs.
  • In the epithelial component, the relative amount of large cysts, medium to small cysts, and phyllodes-type glands was: 65%/25%/10% in CNs versus 25%/40%/35% in MESTs.
  • The epithelial component ranged from flat to cuboidal to hobnail cells in both types of tumors.
  • No significant atypia of either component was seen, although the epithelial cells showed reactive changes.
  • Follow-up in both categories of tumors (mean 3.2 y, median 3 y for CNs and mean 2.5 y, median of 2 y for MESTs) showed no evidence of recurrence or metastases in keeping with their benign nature.
  • This study highlights the remarkable similarity between CN and MEST in sex predilection, age distribution, and morphologic attributes of both the epithelial and stromal components and immunohistochemical profile albeit with variation in individual categories with higher prevalence of stromal to epithelial ratio, prominent ovarian stroma, smaller cysts with phyllodes glands pattern and stromal luteinization being more common in MEST; and large cysts, thin septae and low stromal to epithelial ratio in CN.
  • The presence of ovarian-type stroma and müllerian related immunohistochemical markers raises the possibility that these tumors may originate from müllerian remnants misplaced during embryogenesis.
  • On the basis of detailed morphologic analysis of this series of CN and MEST, we propose a unifying term of "renal epithelial and stromal tumor" (REST) to encompass the spectrum of findings observed in these tumors at least until new molecular studies can prove or disprove this challenging hypothesis.
  • [MeSH-major] Kidney Neoplasms / classification. Kidney Neoplasms / pathology. Neoplasms, Glandular and Epithelial / classification. Neoplasms, Glandular and Epithelial / pathology. Nephroma, Mesoblastic / classification. Nephroma, Mesoblastic / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414095.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


70. Xiang H, Ding W, Liu F, Ren GP, Wang ZM, Zhu XZ: [Clinicopathologic analysis of mixed epithelial and stromal tumor of kidney and adult cystic nephroma]. Zhonghua Bing Li Xue Za Zhi; 2009 Jul;38(7):436-40
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic analysis of mixed epithelial and stromal tumor of kidney and adult cystic nephroma].
  • OBJECTIVE: To study the clinicopathologic features, immunophenotype and differential diagnosis of mixed epithelial and stromal tumor of kidney (MEST) and adult cystic nephroma (CN).
  • One was composed of a mixture of solid and cystic elements, while the remaining case showed a multicystic cut surface bridged by thick fibrous septa.
  • The glandular structures in 2 of the cases were partially lined by endometrial or tubal epithelium.
  • In contrast, the thin-walled cystic spaces in CN were lined by a single layer of epithelium.Immunohistochemical study showed that the epithelial cells were positive for pan-cytokeratin and epithelial membrane antigen.
  • CONCLUSIONS: Both MEST and CN are uncommon renal neoplasm.
  • Most of them run a benign clinical course.
  • [MeSH-major] Epithelial Cells / pathology. Kidney Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Neoplasms, Cystic, Mucinous, and Serous / pathology. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781188.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Desmin; 0 / Receptors, Estrogen; 0 / Vimentin
  •  go-up   go-down


71. Aikhionbare FO, Mehrabi S, Kumaresan K, Zavareh M, Olatinwo M, Odunsi K, Partridge E: Mitochondrial DNA sequence variants in epithelial ovarian tumor subtypes and stages. J Carcinog; 2007 Jan 26;6:1
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitochondrial DNA sequence variants in epithelial ovarian tumor subtypes and stages.
  • BACKGROUND: A majority of primary ovarian neoplasms arise from cell surface epithelium of the ovaries.
  • Although old age and a positive family history are associated risk factors, the etiology of the epithelial ovarian tumors is not completely understood.
  • Additionally, knowledge of factors involved in the histogenesis of the various subtypes of this tumor as well as those factors that promote progression to advanced stages of ovarian malignancy are largely unknown.
  • METHODS: In this study, we determined the presence of polymorphisms and other sequence variants of mitochondrial DNA (mtDNA) in 102 epithelial ovarian tumors including 10 matched normal tissues that paired with some of the tumors.
  • There were relatively high frequencies of three mutations in the 12S rRNA gene at np 772, 773, and 780 in stage IIIC endometrioid tumors, two of which are novel (773delT and 780delC), and occurred with a frequency of 100% (7/7).
  • Furthermore, two mutations were observed in serous tumors only at np 1657 in stage IV (10/10), and at np 8221delA in benign cystadenomas (3/3) and borderline tumors (4/4).
  • A high frequency, 81% (13/16) of TC insertion at np 310 was found only in early stages of serous subtype (benign cystadenomas, 3/3; borderline tumors, 4/4; stage I tumors, 2/5 and matched normal tissues 4/4).
  • CONCLUSION: Our findings indicate that certain mtDNA mutations can reliably distinguish the different histologic subtypes of epithelial ovarian tumors.
  • In addition, these data raise the possibility that certain mtDNA mutations may be useful biomarkers for predicting tumor aggressiveness and may play a potential role in tumorigenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):719-24 [15647368.001]
  • [Cites] Nat Genet. 1998 Nov;20(3):291-3 [9806551.001]
  • [Cites] Biochim Biophys Acta. 1999 Feb 9;1410(2):103-23 [10076021.001]
  • [Cites] Eur J Cancer. 1999 Feb;35(2):316-9 [10448277.001]
  • [Cites] Mutat Res. 1999 Jul 30;434(3):177-203 [10486591.001]
  • [Cites] Science. 2000 Mar 17;287(5460):2017-9 [10720328.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4231-7 [10945635.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5007-11 [11016619.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1843-5 [11280735.001]
  • [Cites] Mutat Res. 2001 May;488(2):119-33 [11344040.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38555-62 [11504725.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):5998-6001 [11507041.001]
  • [Cites] Am J Kidney Dis. 2001 Sep;38(3):529-36 [11532685.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7015-9 [11585726.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7623-6 [11606403.001]
  • [Cites] J Hum Genet. 2002;47(3):122-30 [11950064.001]
  • [Cites] Nucleic Acids Res. 2002 Jul 1;30(13):2817-24 [12087165.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2260-5 [12114429.001]
  • [Cites] J Pathol. 2003 Feb;199(2):237-42 [12533837.001]
  • [Cites] Cancer Lett. 2003 Feb 10;190(1):73-7 [12536079.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1838-43 [12578990.001]
  • [Cites] J Surg Oncol. 2003 Mar;82(3):170-3 [12619060.001]
  • [Cites] Hum Mutat. 2003 Apr;21(4):441-3 [12655558.001]
  • [Cites] Genetics. 1992 Jan;130(1):153-62 [1346260.001]
  • [Cites] Oncogene. 2004 Feb 12;23(6):1314-20 [14647457.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(2):99-105 [14999140.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4466-77 [15016645.001]
  • [Cites] Mol Cancer Res. 2004 Aug;2(8):433-41 [15328370.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:30 [15482594.001]
  • [Cites] BMC Cancer. 2006;6:21 [16433919.001]
  • [Cites] Mutat Res. 2006 Mar 20;595(1-2):42-51 [16472830.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:259-66 [16515601.001]
  • [Cites] Hum Pathol. 1991 Aug;22(8):750-62 [1869263.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] FEBS Lett. 1995 Jan 16;358(1):1-3 [7821417.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:208-18 [8747398.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):514-9 [9012815.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • (PMID = 17257433.001).
  • [ISSN] 1477-3163
  • [Journal-full-title] Journal of carcinogenesis
  • [ISO-abbreviation] J Carcinog
  • [Language] ENG
  • [Grant] United States / NIMHD NIH HHS / MD / P20 MD000272
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC1794240
  •  go-up   go-down


72. An HJ, Kim DS, Park YK, Kim SK, Choi YP, Kang S, Ding B, Cho NH: Comparative proteomics of ovarian epithelial tumors. J Proteome Res; 2006 May;5(5):1082-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative proteomics of ovarian epithelial tumors.
  • We analyzed 12 ovarian epithelial tumors using 2D PAGE-based comparative proteomics to construct intra- and inter-tumoral distance map trees and to discover surrogate biomarkers indicative of an ovarian tumor.
  • The analysis was performed after laser microdissection of 12 fresh-frozen tissue samples, including 4 serous, 5 mucinous, and 3 endometrioid tumors, with correlation with their histopathological characteristics.
  • Ovarian epithelial tumors and normal tissues showed an apparent separation on the distance map tree.
  • All mucinous tumors with aggressive histology were separated from the low malignant potential (LMP) group.
  • The benign-looking cysts adjacent to the intraepithelial carcinoma (IEC) showed an expression pattern identical to that of the IEC area.
  • The potential candidate biomarkers screened in ovarian tumors and found to be significantly up-regulated in comparison to normal tissues were as follows: NM23, annexin-1, protein phosphatase-1, ferritin light chain, proteasome alpha-6, and NAGK (N-acetyl glucosamine kinase).
  • In conclusion, ovarian mucinous tumors are distinct from other ovarian epithelial tumors.
  • LMP mucinous tumors showing histologically aggressive features belong to mucinous carcinoma on the proteomic basis.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Proteomics / methods
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Cluster Analysis. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Middle Aged. Models, Biological. Reference Values. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods


73. Picken MM, Fresco R: Mixed epithelial and stromal tumor of the kidney: preliminary immunohistochemical and electron microscopic studies of the epithelial component. Ultrastruct Pathol; 2005 May-Aug;29(3-4):283-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed epithelial and stromal tumor of the kidney: preliminary immunohistochemical and electron microscopic studies of the epithelial component.
  • Mixed epithelial and stromal tumor of the kidney is a rare biphasic tumor composed of cysts and tubules embedded in the spindle cell stroma.
  • Although the histogenesis of this tumor is unknown, it has been proposed that both components of the tumor, i.e., stromal and epithelial, are neoplastic.
  • The authors report preliminary immunohistochemical and electron microscopic studies of the epithelial component from one case of a typical, benign, mixed epithelial, and stromal tumor of the kidney.
  • By electron microscopy, some tubules had features of proximal tubular epithelium, while other tubules had features of the loop of Henle (thin segments).
  • The authors believe that in a benign tumor such morphologic heterogeneity is inconsistent with neoplastic proliferation.
  • Therefore, they postulate that in mixed epithelial and stromal tumor of the kidney the tubules are entrapped rather than neoplastic.
  • [MeSH-major] Epithelial Cells / pathology. Kidney Neoplasms / pathology. Mixed Tumor, Malignant / pathology. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16036882.001).
  • [ISSN] 0191-3123
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRT7 protein, human; 0 / Keratin-7; 68238-35-7 / Keratins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


74. Ansieau S, Caron de Fromentel C, Bastid J, Morel AP, Puisieux A: [Role of the epithelial-mesenchymal transition during tumor progression]. Bull Cancer; 2010 Jan;97(1):7-15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of the epithelial-mesenchymal transition during tumor progression].
  • [Transliterated title] Rôle de la transition épithéliomésenchymateuse dans la progression tumorale.
  • The epithelial-mesenchymal transition (EMT) is a morphogenetic program that converts epithelial into mesenchymal cells during the embryonic development.
  • This mechanism is frequently reactivated during tumor progression and provides cells with motility and invasive capabilities favoring the metastatic dissemination from epithelial tumors.
  • Various EMT-inducing transcription factors, such as the TWIST proteins, were also shown to inhibit oncogene-induced fail-safe programs (senescence and apoptosis), thereby promoting the progression from benign to malignant stages.
  • Altogether, these observations suggest that EMT could play an important role in favoring both tumor development and metastatic dissemination.
  • [MeSH-major] Cell Transdifferentiation / physiology. Epithelial Cells / pathology. Mesoderm / pathology. Neoplasm Metastasis / pathology
  • [MeSH-minor] Animals. Cell Aging / physiology. Cell Movement / physiology. Disease Progression. Humans. Mice. Neoplasm Invasiveness. Neoplastic Stem Cells / physiology. Signal Transduction / physiology. Transcription Factors / physiology. Transcriptional Activation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026450.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Transcription Factors
  •  go-up   go-down


75. Cardillo MR, Ippoliti F: Interleukin-6, interleukin-10 and heat shock protein-90 expression in renal epithelial neoplasias and surrounding normal-appearing renal parenchyma. Int J Immunopathol Pharmacol; 2007 Jan-Mar;20(1):37-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-6, interleukin-10 and heat shock protein-90 expression in renal epithelial neoplasias and surrounding normal-appearing renal parenchyma.
  • Cytokines, notably the interleukins IL-6 and IL-10, have an important role in the development and progression of renal-cell carcinomas, acting in the host-tumor interaction and in tumor bulk.
  • Heat shock proteins (HSP), in particular HSP-90, may have a regulatory role in cytokine biosynthesis and prognostic implication in some tumors.
  • IL-6, IL-10 and HSP-90 proteins were more strongly expressed in epithelium and stroma of the renal tumoral compartment than in adjacent normal peritumoral tissue.
  • The percentage of cells expressing IL-6, IL-10 and HSP-90 immunoreactivity was higher in benign epithelial tumors, than in normal peritumoral tissue, but lower than in renal-cell carcinomas.
  • Whereas HSP-90 immunoreactivity seemed higher in more aggressive histological phenotypes (collecting-duct carcinoma) of renal-cell carcinomas, IL-10 protein levels were higher in more advanced TNM stage (pT3) tumors.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17346426.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HSP90 Heat-Shock Proteins; 0 / Interleukin-6; 130068-27-8 / Interleukin-10
  •  go-up   go-down


76. Camara O, Kavallaris A, Nöschel H, Rengsberger M, Jörke C, Pachmann K: Seeding of epithelial cells into circulation during surgery for breast cancer: the fate of malignant and benign mobilized cells. World J Surg Oncol; 2006;4:67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seeding of epithelial cells into circulation during surgery for breast cancer: the fate of malignant and benign mobilized cells.
  • BACKGROUND: Surgery of malignant tumors has long been suspected to be the reason for enhancement of growth of metastases with fatal outcome.
  • This often prevented surgeons from touching the tumor if not absolutely necessary.
  • We have shown in lung cancer patients that surgery, itself, leads to mobilization of tumor cells into peripheral blood.
  • Monitoring of tumor cell release during and the fate of such cells after surgery for breast cancer may help to reveal how metastases develop after surgery.
  • METHOD: We used the MAINTRAC analysis, a new tool for online observation of circulating epithelial cells, to monitor the number of epithelial cells before, 30 min, 60 min, three and seven days after surgery and during subsequent variable follow up in breast cancer patients.
  • RESULTS: Circulating epithelial cells were already present before surgery in all patients.
  • They started increasing during the following 3 to 4 days up to thousand fold in 85% of treated patients in spite of complete resection of the tumor with tumor free margins in all patients.
  • This was in contrast to the observation in a patient where surgery was performed for benign condition.
  • Epithelial cells increased up to more than 50,000 after surgery but followed by a complete reduction to below the threshold of detection.
  • CONCLUSION: Frequently before but regularly during surgery of breast cancer, epithelial cells are mobilized into circulation.
  • Part of these cells, most probably normal or apoptotic cells, are cleared from the circulation as also shown to occur in benign conditions.
  • After resection even if complete and of small tumors, cells can remain in the circulation over long times.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Invest. 1994;12(6):559-67 [7994590.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):316-25 [16507828.001]
  • [Cites] Clin Chem Lab Med. 2001 Sep;39(9):811-7 [11601678.001]
  • [Cites] Endocr Relat Cancer. 2001 Dec;8(4):265-86 [11733225.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7737-42 [12808139.001]
  • [Cites] Eur J Cancer. 2003 Aug;39(12):1794-806 [12888376.001]
  • [Cites] Breast Cancer Res Treat. 2003 Dec;82(3):199-206 [14703067.001]
  • [Cites] N Engl J Med. 2004 Aug 19;351(8):824-6 [15317898.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7336-45 [15492254.001]
  • [Cites] Am J Surg Pathol. 2004 Dec;28(12):1641-5 [15577685.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):358-67 [15593354.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8152-62 [15623589.001]
  • [Cites] BMJ. 2005 Jan 29;330(7485):217 [15649903.001]
  • [Cites] Cancer. 2005 Mar 1;103(5):884-91 [15666325.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4698-706 [15930288.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1449-57 [15956037.001]
  • [Cites] Clin Chem Lab Med. 2005;43(6):617-27 [16006258.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5657; author reply 5657-8 [16061886.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):227-39 [16169467.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R975-9 [16280045.001]
  • [Cites] Breast Cancer Res. 2000;2(6):400-7 [11250733.001]
  • (PMID = 17002789.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1599731
  •  go-up   go-down


77. Idahl A, Lundin E, Elgh F, Jurstrand M, Møller JK, Marklund I, Lindgren P, Ottander U: Chlamydia trachomatis, Mycoplasma genitalium, Neisseria gonorrhoeae, human papillomavirus, and polyomavirus are not detectable in human tissue with epithelial ovarian cancer, borderline tumor, or benign conditions. Am J Obstet Gynecol; 2010 Jan;202(1):71.e1-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chlamydia trachomatis, Mycoplasma genitalium, Neisseria gonorrhoeae, human papillomavirus, and polyomavirus are not detectable in human tissue with epithelial ovarian cancer, borderline tumor, or benign conditions.
  • OBJECTIVE: We sought to analyze the presence of the microorganisms Chlamydia trachomatis, Mycoplasma genitalium, Neisseria gonorrhoeae, human papillomavirus (HPV), and the polyomaviruses BK virus (BKV) and JC virus (JCV) in ovarian tissues of women with ovarian carcinomas, borderline tumors, and benign conditions.
  • STUDY DESIGN: Ovarian tissue, snap-frozen and stored at -80 degrees C, from 186 women with benign conditions, borderline tumors, and epithelial ovarian cancer, as well as tissue from the contralateral ovary of 126 of these women, were analyzed regarding presence of C trachomatis and N gonorrhoeae (transcription mediated amplification), M genitalium (real-time polymerase chain reaction [PCR]), HPV (PCR), and BKV and JCV (PCR).
  • CONCLUSION: C trachomatis, M genitalium, N gonorrhoeae, HPV, and the polyomaviruses BKV and JCV are not detectable in ovarian tissues either from women with benign conditions and borderline tumors or from women with ovarian cancer.
  • [MeSH-major] BK Virus / isolation & purification. Chlamydia trachomatis / isolation & purification. Genital Diseases, Female / virology. JC Virus / isolation & purification. Ovarian Neoplasms / virology. Ovary / virology


78. Shekarkhar MJ, Tabei SZ, Kumar PV, Hashemi SB: Cytologic findings in calcifying epithelial odontogenic tumor: a case report. Acta Cytol; 2005 Sep-Oct;49(5):533-6
Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic findings in calcifying epithelial odontogenic tumor: a case report.
  • BACKGROUND: Calcifying epithelial odontogenic tumor (CEOT), or Pindborg's tumor, is a rare, benign, odontogenic neoplasm first described by Pindborg in 1955.
  • It is most commonly seen in the fourth and fifth decades of life, usually arises in the mandibular premolar-molar areas and accounts for approximately 1% of all intraosseous odontogenic tumors.
  • The fine needle aspiration (FNA) smears showed numerous calcifications; amorphous, eosinophilic material; and clusters of round epithelial cells embedded in a bloody background.
  • CONCLUSION: FNA findings of calcifying epithelial odontogenic tumor have been described rarely.
  • The clusters of epithelial cells with prominent nucleoli are mistaken for features of a malignant tumor.
  • [MeSH-major] Calcinosis / pathology. Epithelial Cells / pathology. Jaw Neoplasms / pathology. Maxillary Neoplasms / pathology. Maxillary Sinus Neoplasms / pathology. Odontogenic Tumors / pathology. Palatal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334032.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Uenoyama Y, Seno H, Fukuda A, Sekikawa A, Nanakin A, Sawabu T, Kawada M, Kanda N, Suzuki K, Yada N, Fukui H, Chiba T: Hypoxia induced by benign intestinal epithelial cells is associated with cyclooxygenase-2 expression in stromal cells through AP-1-dependent pathway. Oncogene; 2006 Jun 1;25(23):3277-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia induced by benign intestinal epithelial cells is associated with cyclooxygenase-2 expression in stromal cells through AP-1-dependent pathway.
  • Cyclooxygenase-2 (COX-2) plays important roles in tumor development.
  • Especially in the early-stage colorectal tumors, COX-2 expression is often observed in the tumor stroma.
  • In the present study, we simulated the indirect interaction between epithelial cells and stromal cells in the process of colorectal tumor development using an in vitro co-culture model in which NIH3T3 fibroblasts were co-cultured with 'sparsely' or 'densely' populated intestinal epithelial cells, Intestine-407 as a model of premalignant or benign intestinal epithelial cells, and DLD-1 and Caco-2 as models of malignant epithelial cells.
  • COX-2 expression in NIH3T3 fibroblasts was upregulated when co-cultured with the 'dense' epithelial cells regardless of their character.
  • Interestingly, there was pericellular hypoxia in the vicinity of NIH3T3 fibroblasts when co-cultured with 'dense' epithelial cells, and the recovery of the partial pressure of oxygen level resulted in the reduction of enhanced COX-2 expression only in NIH3T3 fibroblasts co-cultured with 'dense' Intestine-407 cells.
  • Thus, pericellular hypoxia of the stromal cells caused by densely populated epithelial cells may be one of the potent COX-2 enhancers before completion of malignant transformation during intestinal tumor development.
  • [MeSH-minor] Animals. Caco-2 Cells. Cell Count. Cell Line, Tumor. Coculture Techniques. Enzyme Induction / physiology. Humans. Mice. NIH 3T3 Cells. Precancerous Conditions / enzymology. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Stromal Cells / enzymology. Stromal Cells / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16407821.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Transcription Factor AP-1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


80. Kurisetty VV, Johnston PG, Rudland PS, El-Tanani MK: Identification of genes differentially expressed between benign and osteopontin transformed rat mammary epithelial cells. BMC Res Notes; 2009;2:15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of genes differentially expressed between benign and osteopontin transformed rat mammary epithelial cells.
  • BACKGROUND: Osteopontin is a secreted, integrin-binding and phosphorylated acidic glycoprotein which has an important role in tumor progression.
  • FINDINGS: In this study, we have utilized suppressive subtractive hybridization (SSH) to evaluate OPN regulated gene expression, using the Rama 37 benign non-invasive rat mammary cell line and a subclone, Rama 37-OPN.
  • Four of the most differentially expressed genes between the benign and in vitro malignant rat mammary cell lines are tumor protein translationally controlled I (TPTI), aryl hydrocarbon receptor nuclear translocator (ARNT), ataxia telangiectasia mutated (ATM) and RAN GTPase (RAN).
  • CONCLUSION: The results suggest that enhanced properties associated with the malignant state in vitro induced by osteopontin may be due to, in part, overexpression of RAN GTPase and these biological results are the subject of a subsequent publication 1.

  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Rama 37-OPN (CVCL_T288) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2008 Dec 4;27(57):7139-49 [18794800.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1595-603 [10749128.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):17-24 [16003757.001]
  • [Cites] Arq Neuropsiquiatr. 2005 Sep;63(3B):864-9 [16258673.001]
  • [Cites] Breast. 2005 Oct;14(5):360-7 [16216737.001]
  • [Cites] Exp Cell Res. 2005 Oct 15;310(1):205-17 [16125700.001]
  • [Cites] J Cell Biochem. 2005 Aug 1;95(5):875-84 [15844214.001]
  • [Cites] Radiat Oncol Investig. 1999;7(2):55-65 [10333246.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):605-11 [9815727.001]
  • [Cites] Int J Cancer. 1998 Oct 23;79(5):502-8 [9761120.001]
  • [Cites] Oncogene. 1996 Jul 4;13(1):97-104 [8700559.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6025-30 [8650213.001]
  • [Cites] Cancer Res. 1994 Feb 1;54(3):832-7 [8306346.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4162-70 [15205327.001]
  • [Cites] BMC Biotechnol. 2003 Oct 13;3:18 [14552656.001]
  • [Cites] Clin Exp Metastasis. 2004;21(1):49-56 [15065602.001]
  • [Cites] J Urol. 2004 Mar;171(3):1080-4 [14767275.001]
  • [Cites] Magy Seb. 2003 Aug;56(3-4):108-12 [14619093.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):117-30 [12620407.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14976-81 [12399545.001]
  • [Cites] Br J Cancer. 2002 Aug 12;87(4):423-31 [12177779.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3417-27 [12067984.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2A):733-40 [12014644.001]
  • [Cites] Breast Cancer Res Treat. 2001 Dec;70(3):197-204 [11804183.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5619-29 [11454716.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):5828-39 [10913166.001]
  • [Cites] J Biol Chem. 2006 Sep 8;281(36):26587-601 [16807234.001]
  • (PMID = 19192273.001).
  • [ISSN] 1756-0500
  • [Journal-full-title] BMC research notes
  • [ISO-abbreviation] BMC Res Notes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2644310
  •  go-up   go-down


81. Piscioli I, Morelli L, Falzone A, Del Nonno F, Neri M, Di Rocco ZC, Catalucci A, Donato S, Licci S: Epithelial-myoepithelial carcinoma of the parotid gland, unusual malignancy radiologically simulating a benign lesion: case report. Int Semin Surg Oncol; 2007;4:25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial-myoepithelial carcinoma of the parotid gland, unusual malignancy radiologically simulating a benign lesion: case report.
  • BACKGROUND: Ultrasound (US), Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are widely used in the clinical diagnosis of parotid gland tumors and their efficacy in identifying benign lesions is well documented.
  • Only few cases of salivary gland low grade malignant tumors have been previously reported in the literature complete with the radiological features.
  • CASE PRESENTATION: We here describe a case of epithelial-myoepithelial carcinoma (EMC) of the parotid gland, a low grade malignant tumor, with spread to an intraparotid lymph node and with CT and MRI findings mimicking a benign lesion.
  • CONCLUSION: All the images revealed sharply outlined profiles and a homogeneous enhancement of the nodule, suggesting a benign tumor and demonstrating that a radiological evaluation of the lesion alone may be unsatisfactory and misleading in the diagnosis of salivary gland tumours, especially in the case of low grade malignant tumors, such as EMC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2000 Jan;214(1):231-6 [10644130.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2002 Nov;10(4):631-62 [12685498.001]
  • [Cites] Eur Radiol. 2003 Dec;13 Suppl 4:L25-33 [15018162.001]
  • [Cites] Radiology. 1987 Oct;165(1):183-9 [3628768.001]
  • [Cites] Head Neck Surg. 1986 Jan-Feb;8(3):177-84 [3744850.001]
  • [Cites] Virchows Arch A Pathol Pathol Anat. 1972;356(1):16-31 [4340536.001]
  • [Cites] Radiol Clin North Am. 1984 Mar;22(1):145-59 [6709866.001]
  • [Cites] AJR Am J Roentgenol. 1982 Sep;139(3):547-54 [6981322.001]
  • [Cites] Eur Radiol. 2003 May;13(5):964-75 [12695816.001]
  • [Cites] Kulak Burun Bogaz Ihtis Derg. 2003 Apr;10(4):171-4 [12941990.001]
  • [Cites] Australas Radiol. 1999 Nov;43(4):520-2 [10901971.001]
  • [Cites] Tohoku J Exp Med. 1997 Nov;183(3):233-8 [9550131.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Mar;17(3):560-2 [8881253.001]
  • [Cites] J Otolaryngol. 1993 Jun;22(3):176-9 [8396653.001]
  • (PMID = 17939852.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2092427
  •  go-up   go-down


82. Sato K, Ueda Y, Shimasaki M, Ozaki M, Nitta N, Chada K, Ishikawa Y, Katsuda S: Pleomorphic adenoma (benign mixed tumor) of the breast: a case report and review of the literature. Pathol Res Pract; 2005;201(4):333-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic adenoma (benign mixed tumor) of the breast: a case report and review of the literature.
  • We report a case of pleomorphic adenoma (benign mixed tumor) of the breast, which is an extremely rare location for this tumor.
  • Examination of a 55-year-old woman unexpectedly revealed a mass measuring 0.8 cm in diameter in the subareolar region of the right breast.
  • Excisional biopsy was performed, and the tumor histologically showed pleomorphic adenoma composed of duct epithelial cells, myoepithelial cells, and a myxochondroid matrix.
  • Immunohistochemically, duct epithelial cells were positive for the estrogen receptor, but negative for the progesterone receptor.
  • Sixty-nine cases of this type of tumor arising in the breast have been described previously.
  • Using imaging procedures, the tumor has occasionally been misdiagnosed as malignant clinically and even pathologically in frozen section diagnosis.
  • Careful diagnosis based on paraffin sections is required to avoid unnecessary aggressive surgery, and pathologists should include pleomorphic adenoma in the differential diagnosis of a demarcated, juxtaareolar, small hard mass.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. HMGA1a Protein / analysis. HMGA2 Protein / analysis. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Middle Aged. Receptors, Estrogen / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991841.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HMGA2 Protein; 0 / Receptors, Estrogen; 124544-67-8 / HMGA1a Protein
  • [Number-of-references] 32
  •  go-up   go-down


83. Dobrzycka B, Terlikowski SJ, Garbowicz M, Niklińska W, Bernaczyk PS, Nikliński J, Kinalski M, Chyczewski L: Tumor necrosis factor-alpha and its receptors in epithelial ovarian cancer. Folia Histochem Cytobiol; 2009;47(4):609-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor necrosis factor-alpha and its receptors in epithelial ovarian cancer.
  • The aim of the present study was to characterize the expression pattern of tumor necrosis factor (TNF)-alpha and its receptors (TNF-Rs) in the epithelial ovarian cancer (EOC) and compare these results with the outcome of 126 patients.
  • The proportion of samples positive for TNF-alpha and TNF-R2 was higher in epithelial ovarian cancer patients than in benign ovarian diseases (p<0.001 and p=0.016, respectively).
  • Immunostaining intensity of TNF-R2 were correlated with tumor stage (p<0.001) and with reduced mean survival time (MST) (p=0.002).
  • The results of the present study suggested that tissue expression of TNF-R2 in epithelial ovarian cancer was correlated with the highest risk of cancer progression.
  • Thus, the clinical value of activated TNF system in epithelial ovarian cancer needs to be further investigated.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20430728.001).
  • [ISSN] 1897-5631
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Receptors, Tumor Necrosis Factor, Type I; 0 / Receptors, Tumor Necrosis Factor, Type II; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


84. D'Armiento J, Imai K, Schiltz J, Kolesnekova N, Sternberg D, Benson K, Pardo A, Selman M, Smolarek T, Vundavalli M, Sonnet J, Szabolcs M, Chada K: Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis. Cancer Res; 2007 Mar 1;67(5):1902-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis.
  • Previously, HMGA2 was shown to be misexpressed in a number of benign, differentiated mesenchymal tumors including lipomas, uterine leiomyomas, and pulmonary chondroid hamartomas.
  • In contrast, HMGA2 was not expressed in sections of normal adult lung or other proliferative interstitial lung diseases, indicating that the expression of HMGA2 in LAM represents aberrant gene activation and is not due solely to an increase in cellular proliferation.
  • In vivo studies in transgenic mice show that misexpression of HMGA2 in smooth muscle cells resulted in increased proliferation of these cells in the lung surrounding the epithelial cells.


85. Li H, Gu Y, Miki J, Hukku B, McLeod DG, Hei TK, Rhim JS: Malignant transformation of human benign prostate epithelial cells by high linear energy transfer alpha-particles. Int J Oncol; 2007 Sep;31(3):537-44
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of human benign prostate epithelial cells by high linear energy transfer alpha-particles.
  • In the present study, we examined the oncogenic transforming potency of alpha-particles using non-tumorigenic, telomerase-immortalized human benign prostate epithelial cells.
  • We report the malignant transformation of human benign prostate epithelial cells after a single exposure to 0.6 Gy dose of alpha-particles.
  • Transformed cells showed anchorage-independent growth in soft agar and induced progressively growing tumors when transplanted into SCID mice.
  • The tumors were characterized histologically as poorly differentiated adenocarcinomas.
  • The cell line derived from tumor (SCID 5015), like the unirradiated cells, expressed cytokeratin 5, 8 and 18, NKX3.1 and AMACR.
  • Prominent changes in chromosomes 6, 11 and 16, as well as mutations and deletions of the p53 gene were observed in the tumor outgrowth and tumor cells.
  • These findings provide the first evidence of malignant transformation of human benign prostate epithelial cells exposed to a single dose of alpha-particles.
  • [MeSH-minor] Animals. Cell Line, Transformed. Chromosome Aberrations. Humans. Male. Mice. Mice, SCID. Neoplasm Transplantation

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671680.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Greece
  •  go-up   go-down


86. Badiglian Filho L, Oshima CT, De Oliveira Lima F, De Oliveira Costa H, De Sousa Damião R, Gomes TS, Gonçalves WJ: Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer. Oncol Rep; 2009 Feb;21(2):313-20
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer.
  • In order to analyze the canonical and noncanonical Wnt pathway in normal ovary, benign ovarian tumor and ovarian cancer, we evaluated the immunohistochemical expression of Wnt1, Frizzled-1 (FZD1), Wnt5a, Frizzled-5 (FZD5) and beta-catenin.
  • The patients were divided in three groups: group A, epithelial ovarian cancer (n=38); group B, benign epithelial neoplasia (n=28); and group C, normal ovaries (n=26).
  • [MeSH-major] Biomarkers, Tumor / analysis. Frizzled Receptors / biosynthesis. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Wnt Proteins / biosynthesis. beta Catenin / biosynthesis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Neoplasm Staging. Ovary. Prognosis. Signal Transduction / physiology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19148501.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Frizzled Receptors; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


87. Hafezi-Bakhtiari S, Al-Habeeb A, Ghazarian D: Benign mixed tumor of the skin, hypercellular variant: a case report. J Cutan Pathol; 2010 Sep;37(9):e46-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign mixed tumor of the skin, hypercellular variant: a case report.
  • Microscopic examination showed a well-circumscribed dermally located tumor composed of ductal elements lined by double to multiple cell layers of bland cuboidal inner cells and elongated spindled outer cells with areas showing cribriform and solid growth patterns.
  • Immunohistochemical studies revealed positive immunoreactivity for EMA, CEA, CD117, HWMK, LWMK, CK7, Androgen receptor and S100 in the ductal (epithelial) cells and positive immunereactivity for calponin, SMA, CK 5/6 and p63 in the myoepithelial component.
  • The overall morphology and immunohistochemical profile are that of a benign cutanoues mixed tumor (chondroid syringoma).
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cell Nucleus / pathology. Diagnosis, Differential. Epidermal Cyst / diagnosis. Humans. Immunohistochemistry. Male. Scalp

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19614993.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


88. Burghaus S, Hölsken A, Buchfelder M, Fahlbusch R, Riederer BM, Hans V, Blümcke I, Buslei R: A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas. Virchows Arch; 2010 Mar;456(3):287-300
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas.
  • Craniopharyngiomas (CP) are benign epithelial tumors of the sellar region and can be clinicopathologically distinguished into adamantinomatous (adaCP) and papillary (papCP) variants.
  • Herein, we characterized the cellular interface between the tumor and the surrounding brain tissue in 48 CP (41 adaCP and seven papCP) compared to non-neuroepithelial tumors, i.e., 12 cavernous hemangiomas, 10 meningiomas, and 14 metastases using antibodies directed against glial fibrillary acid protein (GFAP), vimentin, nestin, microtubule-associated protein 2 (MAP2) splice variants, and tenascin-C.
  • We identified a specific cell population characterized by the coexpression of nestin, MAP2, and GFAP within the invasion niche of the adamantinomatous subtype.
  • Furthermore, the outer tumor cell layer of adaCP showed a distinct expression of MAP2, a novel finding helpful in the differential diagnosis of epithelial tumors in the sellar region.
  • Our data support the hypothesis that adaCP, unlike other non-neuroepithelial tumors of the central nervous system, create a tumor-specific cellular environment at the tumor-brain junction.
  • Whether this facilitates the characteristic infiltrative growth pattern or is the consequence of an activated Wnt signaling pathway, detectable in 90% of these tumors, will need further consideration.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Brain / metabolism. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Glial Fibrillary Acidic Protein / metabolism. Humans. Intermediate Filament Proteins / metabolism. Male. Microtubule-Associated Proteins / metabolism. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology. Nerve Tissue Proteins / metabolism. Nestin. Tenascin / metabolism. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20069432.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / Microtubule-Associated Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Tenascin; 0 / Vimentin
  •  go-up   go-down


89. Jiang Y, Chen Y, Gao L, Ye Q, Alonso MA: [Expression pattern of MAL in normal epithelial cells, benign tumor, and squamous cell carcinoma of larynx]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 May;23(10):451-3
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression pattern of MAL in normal epithelial cells, benign tumor, and squamous cell carcinoma of larynx].
  • METHOD: Use the immunohistochemical technique to analyze the distribution of MAL in normal laryngeal epithelial cells, polyp of vocal cords, laryngeal atypical hyperplasia and laryngeal squamous cell carcinoma.
  • RESULT: MAL-like immunohistochemical reactions are strongly expressed in normal laryngeal epithelial cells and its expression is no significantly different in epithelial cells of the polyp of vocal cords.
  • CONCLUSION: MAL is normally expressed in laryngeal epithelial cells and its expression changes at early stages of carcinoma development.
  • [MeSH-minor] Case-Control Studies. Double-Blind Method. Epithelial Cells / metabolism. Humans. Myelin and Lymphocyte-Associated Proteolipid Proteins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19670627.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / MAL protein, human; 0 / Membrane Transport Proteins; 0 / Myelin Proteins; 0 / Myelin and Lymphocyte-Associated Proteolipid Proteins; 0 / Proteolipids
  •  go-up   go-down


90. Thomassin-Naggara I, Bazot M, Daraï E, Callard P, Thomassin J, Cuenod CA: Epithelial ovarian tumors: value of dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis. Radiology; 2008 Jul;248(1):148-59
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial ovarian tumors: value of dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis.
  • PURPOSE: To retrospectively evaluate the diagnostic performance of dynamic contrast material-enhanced magnetic resonance (MR) imaging for the characterization of ovarian epithelial tumors, by using histologic findings as the reference standard, and to correlate dynamic contrast-enhanced MR imaging findings with angiogenesis biomarkers.
  • Forty-one women (age range, 22-73 years) with 48 epithelial ovarian tumors underwent dynamic contrast-enhanced MR imaging before surgical excision.
  • In case of bilateral tumors (n = 7), only the most complex tumor was analyzed.
  • Thus, 41 tumors (12 benign, 13 borderline, and 16 invasive) were examined with dynamic contrast-enhanced MR imaging and immunohistochemical methods.
  • RESULTS: EA was higher for invasive tumors than for benign (P < .001) and borderline (P < .05) tumors.
  • T(max) was longer for benign tumors than for borderline (P < .05) and invasive (P < .01) tumors.
  • MS was steeper for invasive tumors than for benign (P < .001) and borderline (P < .001) tumors.
  • PCI was lower in invasive tumors than in borderline (P < .05) and benign (P < .05) tumors.
  • Microvessels showed stronger immunohistochemical VEGFR-2 expression in invasive tumors than in benign or borderline tumors (P < .05).
  • MS correlated with a lower PCI (r = -0.34, P = .04) and stronger VEGFR-2 expression by using both epithelial (r = 0.41, P < .01) and endothelial (r = 0.66, P < .001) cells.
  • CONCLUSION: The early enhancement patterns of ovarian epithelial tumors on dynamic contrast-enhanced MR images can help distinguish among benign, borderline, and invasive tumors and were found to correlate with tumoral angiogenic status.
  • [MeSH-major] Image Enhancement / methods. Magnetic Resonance Imaging / methods. Meglumine. Neoplasms, Glandular and Epithelial / diagnosis. Neovascularization, Pathologic / diagnosis. Organometallic Compounds. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2008.
  • (PMID = 18458244.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; 0 / gadoterate meglumine; 6HG8UB2MUY / Meglumine
  •  go-up   go-down


91. Lane BR, Campbell SC, Remer EM, Fergany AF, Williams SB, Novick AC, Weight CJ, Magi-Galluzzi C, Zhou M: Adult cystic nephroma and mixed epithelial and stromal tumor of the kidney: clinical, radiographic, and pathologic characteristics. Urology; 2008 Jun;71(6):1142-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult cystic nephroma and mixed epithelial and stromal tumor of the kidney: clinical, radiographic, and pathologic characteristics.
  • OBJECTIVES: Adult cystic nephroma (CN) and mixed epithelial and stromal tumor (MEST) are benign renal tumors readily distinguished from cystic renal cell carcinoma and other malignant variants based on histopathology.
  • METHODS: Pathology of 22 CN (21 patients) and 10 MEST (9 patients) treated between 1987 and 2005 was re-reviewed according to 2004 WHO classification.
  • Nephron-sparing surgery was performed for 16 tumors (50%), including 5 suspected preoperatively and 3 that were 7 cm or greater.
  • At mean follow-up of 4.5 years (range: 1 to 18), no patient had novel or recurrent tumors develop.
  • Pedunculation of a multiloculated cystic lesion may allow for preoperative suspicion of these lesions in the proper clinical setting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313107.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Gu Y, Li H, Miki J, Kim KH, Furusato B, Sesterhenn IA, Chu WS, McLeod DG, Srivastava S, Ewing CM, Isaacs WB, Rhim JS: Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines. Exp Cell Res; 2006 Apr 1;312(6):831-43
Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines.
  • Cell lines ideal for the study of human primary prostate tumors would be those derived from spontaneously immortalized tumor cells; unfortunately, explanted primary prostate cells survive only short-term in culture, and rarely immortalize spontaneously.
  • Therefore, we recently have generated five immortal human prostate epithelial cell cultures derived from both the benign and malignant tissues of prostate cancer patients with telomerase, a gene that prevents cellular senescence.
  • Examination of these cell lines for their morphologies and proliferative capacities, their abilities to grow in low serum, to respond to androgen stimulation, to grow above the agar layer, to form tumors in SCID mice, suggests that they may serve as valid, useful tools for the elucidation of early events in prostate tumorigenesis.
  • Furthermore, the chromosome alterations observed in these immortalized cell lines expressing aspects of the malignant phenotypes imply that these cell lines accurately recapitulate the genetic composition of primary tumors.
  • [MeSH-major] DNA-Binding Proteins / metabolism. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Telomerase / metabolism. Tumor Cells, Cultured
  • [MeSH-minor] Adult. Aged. Animals. Cell Aggregation / physiology. Cell Proliferation. Chromosomes, Human / genetics. Cytogenetic Analysis. Dihydrotestosterone / pharmacology. Gene Expression Profiling. Humans. Immunohistochemistry. Male. Mice. Mice, SCID. Middle Aged. Neoplasm Transplantation. Neoplasms, Experimental / metabolism. Phenotype. Racemases and Epimerases / genetics. Receptors, Androgen / drug effects. Receptors, Androgen / genetics. Reverse Transcriptase Polymerase Chain Reaction. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16413016.001).
  • [ISSN] 0014-4827
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AR protein, human; 0 / DNA-Binding Proteins; 0 / Receptors, Androgen; 08J2K08A3Y / Dihydrotestosterone; EC 2.7.7.49 / Telomerase; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


93. Hart WR: Borderline epithelial tumors of the ovary. Mod Pathol; 2005 Feb;18 Suppl 2:S33-50
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Borderline epithelial tumors of the ovary.
  • The concept and terminology of borderline epithelial tumors of the ovary have been controversial for over a century, in spite of the acceptance of a borderline category in almost all current classifications of ovarian tumors.
  • Typically, borderline tumors are noninvasive neoplasms that have nuclear abnormalities and mitotic activity intermediate between benign and malignant tumors of similar cell type.
  • Borderline tumors of all surface epithelial cell types have been studied.
  • The most common and best understood are serous borderline tumors and mucinous borderline tumors of intestinal type, which are the subject of this review.
  • Some of the most challenging issues for serous tumors include: the criteria and clinical behavior of stromal microinvasion; the high prevalence of synchronous extraovarian disease; the classification and histopathologic features of associated peritoneal tumor implants, especially invasive implants; and, the prognostic significance of micropapillary tumors.
  • The mucinous borderline tumors of intestinal type have a different set of considerations, including: their frequently heterogeneous composition with coexisting benign, borderline and malignant elements; the classification and significance of accompanying noninvasive carcinoma; the recognition of stromal invasion, including microinvasion and expansile invasion; and, the historically misunderstood relationship to pseudomyxoma peritonei.
  • All of these issues are discussed in this presentation, as are the important gross and microscopic features of serous and mucinous borderline tumors and pertinent information on their treatment and prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15761465.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 93
  •  go-up   go-down


94. Chu LC, Hruban RH, Horton KM, Fishman EK: Mixed epithelial and stromal tumor of the kidney: radiologic-pathologic correlation. Radiographics; 2010 Oct;30(6):1541-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed epithelial and stromal tumor of the kidney: radiologic-pathologic correlation.
  • Mixed epithelial and stromal tumor (MEST) of the kidney is a rare, typically benign lesion that occurs predominantly in perimenopausal women.
  • MEST may mimic a variety of benign and malignant renal lesions, such as adult cystic nephroma, complex renal cyst, and cystic renal cell carcinoma.
  • [MeSH-major] Kidney Neoplasms / radiography. Neoplasms, Complex and Mixed / diagnosis. Neoplasms, Glandular and Epithelial / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © RSNA, 2010.
  • (PMID = 21071374.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


95. Richter M, Meyer W, Küster J, Middel P: Exophytic benign mixed epithelial stromal tumour of the kidney: case report of a rare tumour entity. Diagn Pathol; 2010;5:16
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exophytic benign mixed epithelial stromal tumour of the kidney: case report of a rare tumour entity.
  • BACKGROUND: Mixed epithelial and stromal tumour (MEST) represents a recently described benign composite neoplasm of the kidney, which predominantly affects perimenopausal females.
  • Most tumours are benign, although rare malignant cases have been observed.
  • Surgical exploration showed a tumour arising from the lower anterior hilus of the left kidney.
  • The tumour could be excised by preserving the kidney.
  • By intraoperative frozen section the tumour showed characteristic features of MEST with epithelial-covered cysts embedded in an "ovarian-like" stroma.
  • Additional immunohistochemistry investigations showed expression for hormone receptors by the stromal component of the tumour.
  • Commonly, the tumour arises from the renal parenchyma or pelvis.
  • The tumour is composed of an admixture of cystic and sometimes more solid areas.
  • CONCLUSION: MEST represents a distinctive benign tumour entity of the kidney, which affects perimenopausal woman.
  • The tumour should be distinguished from other cystic renal neoplasms.
  • By imaging studies it is difficult to distinguish between a benign or malignant nature of the tumour.
  • [MeSH-major] Epithelial Cells / pathology. Kidney Neoplasms / pathology. Mixed Tumor, Malignant / pathology. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ultrastruct Pathol. 2005 May-Aug;29(3-4):283-6 [16036882.001]
  • [Cites] Lancet Oncol. 2004 Dec;5(12):747-9 [15581546.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):489-500 [17414095.001]
  • [Cites] Pathology. 2007 Apr;39(2):235-40 [17454754.001]
  • [Cites] Mod Pathol. 2008 Jan;21(1):60-5 [17873894.001]
  • [Cites] Urology. 2008 Jun;71(6):1142-8 [18313107.001]
  • [Cites] Eur Urol. 2008 Dec;54(6):1237-46 [18006141.001]
  • [Cites] Eur Urol. 2008 Dec;54(6):1245-6 [18006142.001]
  • [Cites] Am J Surg Pathol. 2009 Jan;33(1):72-80 [18971776.001]
  • [Cites] APMIS. 2008 Nov;116(11):1013-5 [19133001.001]
  • [Cites] Pathology. 2009;41(4):403-6 [19404861.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):958-70 [10895818.001]
  • [Cites] J Urol. 2001 Oct;166(4):1381-2 [11547080.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):700-2 [11764393.001]
  • [Cites] Histopathology. 2004 Mar;44(3):302-4 [14987239.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):359-67 [15322873.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):2-20 [9503503.001]
  • [Cites] Pathol Res Pract. 1998;194(6):445-8 [9689654.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jan;130(1):80-5 [16390243.001]
  • (PMID = 20193076.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2842239
  • [General-notes] NLM/ Original DateCompleted: 20100609
  •  go-up   go-down


96. Shanmuga PS, Ravikumar A, Krishnarathnam K, Rajendiran S: Intraosseous calcifying epithelial odontogenic tumor in a case with multiple myeloma. J Oral Maxillofac Pathol; 2009 Jan;13(1):10-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraosseous calcifying epithelial odontogenic tumor in a case with multiple myeloma.
  • Calcifying epithelial odontogenic tumor (CEOT), also known as Pindborg tumor, is a rare benign odontogenic tumor of locally aggressive behavior.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Braz Dent J. 2006;17(2):171-4 [16924348.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 May;83(5):577-83 [9159818.001]
  • [Cites] Am J Surg Pathol. 1997 Feb;21(2):179-86 [9042284.001]
  • [Cites] J Laryngol Otol. 1996 Aug;110(8):757-62 [8869610.001]
  • [Cites] Laryngoscope. 1983 May;93(5):635-8 [6843256.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Mar;93(3):287-95 [11925538.001]
  • [Cites] Head Neck. 2001 Aug;23(8):692-6 [11443753.001]
  • [Cites] Oral Oncol. 2000 Jan;36(1):17-26 [10889914.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Nov;90(5):656-62 [11077393.001]
  • [Cites] Dentomaxillofac Radiol. 2001 Jan;30(1):22-8 [11175269.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jun;124(6):872-6 [10835524.001]
  • (PMID = 21886990.001).
  • [ISSN] 0973-029X
  • [Journal-full-title] Journal of oral and maxillofacial pathology : JOMFP
  • [ISO-abbreviation] J Oral Maxillofac Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3162847
  • [Keywords] NOTNLM ; Amyloid / calcifying epithelial odontogenic tumor / maxilla / multiple myeloma
  •  go-up   go-down


97. Chang T, Husain AN, Colby T, Taxy JB, Welch WR, Cheung OY, Early A, Travis W, Krausz T: Pneumocytic adenomyoepithelioma: a distinctive lung tumor with epithelial, myoepithelial, and pneumocytic differentiation. Am J Surg Pathol; 2007 Apr;31(4):562-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pneumocytic adenomyoepithelioma: a distinctive lung tumor with epithelial, myoepithelial, and pneumocytic differentiation.
  • Pulmonary tumors with epithelial and myoepithelial differentiation are rare, thought to be of bronchial minor salivary gland origin and classified similarly to salivary gland neoplasms.
  • We report a series of a distinctive subtype of pulmonary glandular tumors showing epithelial and myoepithelial differentiation with further pneumocytic specialization.
  • The tumors were grossly circumscribed, 0.8 to 2.6 cm in greatest dimension, and histologically showed glandular and spindle cell differentiation.
  • Some glands were filled with colloidlike secretion and had an inner, cuboidal epithelial cell layer (pankeratin, epithelial membrane antigen, and thyroid transcription factor-1 positive), surrounded by an outer layer of myoepithelial cells merging with foci of spindled myoepithelial cells (high molecular weight keratin, S100, smooth muscle actin, calponin, caldesmon, and p63 positive).
  • There were also some glands lined by a single layer of plump cells that were positive for surfactant protein-A in addition to the other epithelial cell markers.
  • The biologic behavior to date has been benign.
  • This is the first reported series of a distinctive lung tumor with epithelial, myoepithelial, and pneumocytic differentiation that differs histologically from all previously recognized pulmonary salivary gland-type and pneumocytic tumors.
  • It is a unique benign appearing neoplasm for which the designation pneumocytic adenomyoepithelioma is suggested.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Microscopy, Electron, Transmission. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414103.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


98. Serin IS, Tanriverdi F, Ata CD, Akalin H, Ozcelik B, Ozkul Y, Kelestimur F: GnRH-II mRNA expression in tumor tissue and peripheral blood mononuclear cells (PBMCs) in patients with malignant and benign ovarian tumors. Eur J Obstet Gynecol Reprod Biol; 2010 Mar;149(1):92-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GnRH-II mRNA expression in tumor tissue and peripheral blood mononuclear cells (PBMCs) in patients with malignant and benign ovarian tumors.
  • OBJECTIVE: To investigate the expression of the second form of GnRH (GnRH-II) in tumor tissue and peripheral blood mononuclear cells (PBMCs) in malignant and benign ovarian tumors in humans.
  • STUDY DESIGN: Sixty-six women were studied: 24 with epithelial ovarian carcinomas, 22 with benign ovarian tumors and 20 in the control group undergoing surgery.
  • Malignant, benign and normal ovarian tissue and PBMCs were obtained for measurement of GnRH-II mRNA levels using quantitative real-time RT-PCR.
  • RESULT(S): The expression of GnRH-II was found to be 1.5 times higher in malignant ovarian tumors compared with benign ovarian tumors and the control group in post-menopausal patients (P<0.01).
  • In the post-menopausal patient group with malignant ovarian tumors, there were significant positive correlations between serum FSH level and ovarian tissue GnRH-II mRNA expression (r=0.68; P=0.03), and serum LH level and ovarian tissue GnRH-II mRNA expression (r=0.71; P=0.02).
  • Controls, benign and malignant groups were similar in terms of GnRH-II expression in PBMCs in the pre- and post-menopausal periods.
  • These preliminary data suggest that local GnRH-II may participate in the regulation of ovarian tumor growth in post-menopausal women.
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Postmenopause / genetics. Postmenopause / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20018426.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / RNA, Messenger; 33515-09-2 / Gonadotropin-Releasing Hormone; 91097-16-4 / LHRH, His(5)-Trp(7)-Tyr(8)-
  •  go-up   go-down


99. Bereman MS, Williams TI, Muddiman DC: Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients. Anal Chem; 2009 Feb 1;81(3):1130-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients.
  • In addition, data are compared among samples derived from 10 healthy controls, 10 controls with a differential diagnosis of benign gynecologic tumors, and 10 diseased epithelial ovarian cancer patients (EOC).
  • However, these same glycans provided a significantly less diagnostic value when used to differentiate EOC from benign tumor control samples with an area under the curve of 0.73.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma / diagnosis. Chromatography, Liquid / methods. Glycoproteins / blood. Ovarian Neoplasms / diagnosis. Polysaccharides / blood. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):4-8 [10580125.001]
  • [Cites] Anal Chem. 2008 Oct 1;80(19):7534-42 [18778038.001]
  • [Cites] Fresenius J Anal Chem. 2000 Mar-Apr;366(6-7):669-76 [11225778.001]
  • [Cites] Biochem J. 2001 Jul 1;357(Pt 1):167-82 [11415447.001]
  • [Cites] Rapid Commun Mass Spectrom. 2001;15(19):1862-8 [11565105.001]
  • [Cites] J Am Soc Mass Spectrom. 2002 Apr;13(4):402-7 [11951978.001]
  • [Cites] Cancer Metastasis Rev. 2001;20(3-4):245-77 [12085965.001]
  • [Cites] Rapid Commun Mass Spectrom. 2002;16(13):1320-9 [12112260.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10231-3 [12149519.001]
  • [Cites] J Chromatogr A. 2002 Aug 30;968(1-2):89-100 [12236519.001]
  • [Cites] Anal Biochem. 2003 May 1;316(1):15-22 [12694722.001]
  • [Cites] Clin Exp Metastasis. 2003;20(2):143-52 [12705635.001]
  • [Cites] J Biol Chem. 2003 Aug 1;278(31):28619-34 [12734200.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] Anal Chem. 2004 Feb 1;76(3):833-8 [14750882.001]
  • [Cites] Mass Spectrom Rev. 2004 May-Jun;23(3):161-227 [14966796.001]
  • [Cites] Rapid Commun Mass Spectrom. 2004;18(19):2282-92 [15384149.001]
  • [Cites] J Natl Cancer Inst. 1978 Oct;61(4):961-5 [309009.001]
  • [Cites] J Chromatogr. 1979 Apr 11;162(4):507-28 [528665.001]
  • [Cites] Anal Biochem. 1982 Jan 15;119(2):351-9 [7041698.001]
  • [Cites] Anal Chem. 1990 Feb 1;62(3):248-52 [2305955.001]
  • [Cites] J Chromatogr. 1990 Jan 19;499:177-96 [2324207.001]
  • [Cites] Methods Enzymol. 1990;193:647-60 [2074840.001]
  • [Cites] J Chromatogr. 1993 Sep 3;646(2):317-26 [8408434.001]
  • [Cites] Anal Chem. 1996 Sep 15;68(18):3215-23 [8797382.001]
  • [Cites] Anal Chem. 1997 Nov 15;69(22):4530-5 [9375514.001]
  • [Cites] Anal Chem. 1998 Dec 1;70(23):4951-9 [9852781.001]
  • [Cites] Bioessays. 1999 May;21(5):412-21 [10376012.001]
  • [Cites] Biochemistry. 1964 Jan;3:113-20 [14114492.001]
  • [Cites] Anal Chem. 2005 Feb 1;77(3):886-94 [15679358.001]
  • [Cites] Glycobiology. 2005 Dec;15(12):1332-40 [16037490.001]
  • [Cites] Mol Cell Proteomics. 2005 Dec;4(12):2010-21 [16249172.001]
  • [Cites] Proteomics. 2005 Dec;5(18):4665-72 [16281179.001]
  • [Cites] Glycobiology. 2006 Feb;16(2):132-45 [16177264.001]
  • [Cites] J Chromatogr A. 2006 Jan 27;1103(2):296-306 [16364349.001]
  • [Cites] J Proteome Res. 2006 Jul;5(7):1626-35 [16823970.001]
  • [Cites] Mol Cell Proteomics. 2007 Jan;6(1):43-55 [16847285.001]
  • [Cites] Rapid Commun Mass Spectrom. 2007;21(5):807-11 [17279479.001]
  • [Cites] Anal Chem. 2007 Jul 1;79(13):5051-7 [17539604.001]
  • [Cites] J Proteome Res. 2007 Aug;6(8):2936-62 [17583933.001]
  • [Cites] Biochemistry. 2008 Mar 11;47(10):3155-61 [18260648.001]
  • [Cites] J Proteome Res. 2008 Mar;7(3):1109-17 [18237112.001]
  • [Cites] Proteomics. 2008 Apr;8(7):1384-97 [18318007.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1650-9 [18311910.001]
  • [Cites] Anal Bioanal Chem. 2008 May;391(1):289-97 [18327675.001]
  • [Cites] J Proteome Res. 2008 Jun;7(6):2562-8 [18422354.001]
  • [Cites] Clin Chem. 2008 Jul;54(7):1166-75 [18487288.001]
  • [Cites] Anal Chem. 2008 Aug 1;80(15):6119-26 [18593198.001]
  • [Cites] J Am Soc Mass Spectrom. 2008 Aug;19(8):1138-46 [18511294.001]
  • [Cites] J Mass Spectrom. 2008 Sep;43(9):1215-23 [18324610.001]
  • [Cites] J Proteome Res. 2008 Sep;7(9):3776-88 [18642944.001]
  • [Cites] Mass Spectrom Rev. 1999 Nov-Dec;18(6):349-450 [10639030.001]
  • (PMID = 19113831.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R33 CA105295; United States / NCI NIH HHS / CA / R33 CA105295
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Lectins; 0 / Polysaccharides; 0 / fucose-binding lectin
  • [Other-IDs] NLM/ NIHMS496567; NLM/ PMC3739471
  •  go-up   go-down


100. Rose A, Xu Y, Chen Z, Fan Z, Stamey TA, McNeal JE, Caldwell M, Peehl DM: Comparative gene and protein expression in primary cultures of epithelial cells from benign prostatic hyperplasia and prostate cancer. Cancer Lett; 2005 Sep 28;227(2):213-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative gene and protein expression in primary cultures of epithelial cells from benign prostatic hyperplasia and prostate cancer.
  • Primary cultures are widely used to investigate the disease-specific biology of prostate cancer and benign prostatic hyperplasia (BPH).
  • To identify genes differentially expressed between epithelial cells cultured from adenocarcinomas versus BPH tissues, we used probe array technology.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / metabolism. Gene Expression Profiling. Oligonucleotide Array Sequence Analysis. Prostatic Hyperplasia / genetics. Prostatic Neoplasms / genetics
  • [MeSH-minor] Cell Proliferation. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Immunoblotting. Male. Reverse Transcriptase Polymerase Chain Reaction. Tissue Culture Techniques. Tumor Cells, Cultured






Advertisement